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Abstract 
 
Myasthenia gravis (MG) is an autoimmune disease in which pathogenic antibodies block, target or 
destroy the acetylcholine receptors of the muscle endplate resulting in failure of neuromuscular 
transmission and fatigable weakness. We have previously shown that a subpopulation of South 
African MG patients of African genetic ancestry develop a severe extraocular muscle (EOM) 
phenotype whilst receiving standard immunosuppressive drug therapies. This phenotype associates 
with a functional c.-198C>G SNP (C>G SNP) in the regulatory region of decay accelerating factor 
(DAF), a complement regulatory protein, which is essential for protection against complement-
mediated damage. MG patients are treated with prednisone as the first-line immunosuppressant 
and frequently, an additional steroid-sparing agent, such as azathioprine, cyclosporin A or 
methotrexate. We hypothesised that MG patients with the C>G SNP when treated with 
immunosuppressant drugs, may have lower DAF protein levels contributing to increased 
susceptibility to autologous complement-mediated damage at their EOMs. This study tests this by 
comparing the effect of prednisone, azathioprine, cyclosporine and methotrexate individually and 
prednisone in combination with each of these steroid-sparing agents on wild-type and C>G DAF 
protein (western blotting) and mRNA (quantitative real time PCR) levels and promoter activity 
(luciferase reporter assays). These experiments were performed in EBV transformed lymphoblastoid 
cell lines from control individuals with wild-type DAF and MG patients carrying the C>G SNP. As a 
more representative model for this study the experiments were repeated in mouse skeletal muscle 
cells because there was no available EOM cell line. In support of the hypothesis of this study, 
prednisone, cyclosporin A and azathioprine individually was shown to repress C>G DAF protein levels 
while having either no effect on wild-type DAF or slightly activating it. Importantly, methotrexate 
was the only drug that was able to increase C>G DAF lymphoblast protein expression and therefore 
holds promise as a potentially effective treatment for MG patients with the C>G SNP. Moreover, 
using a calcein assay, clinically relevant doses of prednisone in combination with MG patient sera 
was shown to significantly increase the susceptibility of C>G DAF lymphoblasts to cell lysis (82% C>G 
DAF lymphoblasts vs. 9% wild-type DAF lymphoblasts). These results suggest that MG patient sera 
contain factor(s) that together with prednisone may also be responsible for the susceptibility of the 
EOMs in these patients to injury. The results show that the levels of DAF protein and mRNA did not 
always match which suggests that the drugs tested may regulate the DAF protein at a post-
transcriptional level. In a mouse skeletal muscle model, Daf (equivalent to human wild-type DAF) 
protein expression was consistently repressed by prednisone treatment but activated by cyclosporin 
A, azathioprine and methotrexate. Furthermore, co-treatment of prednisone with either of the 
steroid-sparing drugs showed that azathioprine, and low doses of cyclosporin A and methotrexate 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xiv 
 
were able to overcome the repressive effect of prednisone-only treatment on Daf expression. These 
observations indicate that the regulation of Daf may be species and/or cell-type specific. Together 
the results from this thesis suggest that in EOMs, where DAF is already downregulated, compared to 
other muscles, our MG patients with the C>G SNP may have an increased susceptibility to 
complement-mediated damage when treated with prednisone, which further represses C>G DAF 
expression.    
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Myasthenia gravis 
Myasthenia gravis (MG) is an autoimmune disorder in which auto-antibodies are directed towards 
the acetylcholine receptors located at the neuromuscular junction. As a result, neuromuscular 
transmission is impaired causing fluctuating muscle weakness that worsens after prolonged or 
continued use of muscle, but improves after periods of rest. Historically the term myasthenia gravis 
is of Greek origin with the word myasthenia derived from a combination of the nouns ‘muscle’ and 
‘weakness’ and the addition of gravis that translates to severe (Keesey, 2002). It is believed that the 
first case of MG was documented in 1664 presenting in the American Indian chief 
Opechancanough; however, the first modern description of MG symptoms in patients would only 
be published more than two centuries later.  
Today the global incidence rate of MG is estimated at 200-400 cases per million with the majority of 
patients initially presenting with fatigable weakness in their extraocular muscles (EOMs). 
Consequently, depending on the severity, patients’ vision is often impaired as a result of eyelid 
drooping. The EOMs include a group of six small skeletal muscles which control movement of the 
eyeball in the socket as well as an additional muscle outside the socket, the levator palpebrae 
superioris, which is responsible for elevating the eyelid. In approximately 90% of MG patients the 
symptoms progress from the EOMs to additionally include the bulbar and limb muscles leading to 
what is known as generalised MG. However, if the symptoms remain confined to the EOMs for 
more than two years these individuals are classified as having ocular MG. For 15%-20% of MG 
patients a life-threatening complication known as “myasthenic crisis” occurs in which respiratory 
failure develops that requires hospitalization and mechanical ventilation. 
Using serum-based radioimmunoassay analysis MG can be further grouped into either 
“seropositive” or “seronegative”. Approximately 85%-90% of MG patients are seropositive as they 
contain antibodies in their serum that are directed towards the nicotinic acetylcholine receptor 
(AChR) of the neuromuscular endplate. Another cohort of MG patients contains autoantibodies that 
target the muscle-specific kinases although this type is very uncommon. The remaining 10% are 
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classified as seronegative, as with standard assays no detectable anti-AChR antibodies are in their 
serum. In the Cape region of South Africa the incidence of seropositive MG was found to be similar 
to that of other developing countries although the remaining areas in South Africa showed a lower 
apparent incidence. The latter is likely the result of under recognition and diagnosis of MG where 
access to health care may be suboptimal (Bateman et al., 2005).  
1.2 The neuromuscular junction and MG (see Figure 1.1) 
The neuromuscular junction is the area of contact between terminal nerve endings and muscle 
fibres and is also known as the muscle endplate. In seropositive MG, the pathogenic antibodies are 
targeted to the alpha subunit of AChR which is located in the plasma membrane of the muscle fibre 
of the neuromuscular junction. The axons of the nerve endings contain synaptic vesicles that are 
filled with the neurotransmitter acetylcholine which is released when the action potential arrives at 
the axonal terminal. The acetylcholine then diffuses across the synapse and binds to the AChRs 
located on the crests of the postsynaptic folds of the muscle endplate. Upon binding, Ca2+ channels 
are opened, resulting in depolarization along the muscle fibre causing the muscle to contract (Wray 
and Porter, 1993). Previous studies have shown that the neuromuscular junctions of different 
skeletal muscle types show anatomical and physiological variation, some of which may influence 
their susceptibility to MG. In particular, there is extensive evidence that the unique properties of 
the EOMs render them susceptible to involvement in certain disorders including MG (Soltys et al., 
2008)  
1.3 MG and extraocular muscle susceptibility 
The EOMs are a complex specialised group of muscles required for rapid, accurate movement of 
the orbits for both voluntary and reflex responses. Their high specialization contributes to 
distinctive properties including fast contractile rates, high resistance to fatigue and ability to 
maintain contractions (Soltys et al., 2008). As a result of this uniqueness they differ from skeletal 
muscles both anatomically and physiologically. The EOMs are comprised both of singly innervated 
fibres, like those present in skeletal muscle, and in addition multiple innervated fibres that are 
known for their high oxidative activity (Wasicky et al., 2000). A further unique property of EOMs is 
the co-expression of both fetal and adult forms of the AChR subunits in their neuromuscular 
junctions (Kaminski et al., 1996). Furthermore, the neuromuscular junctions have been shown to  
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Figure 1.1: Structure of the neuromuscular junction. Vesicles at the terminal end of the axon releases 
acetylcholine (Ach) which diffuses across the synaptic cleft and attaches to the acetylcholine receptors 
(AChRs) on the postsynaptic membrane leading to muscle contraction (adapted from 
http://www.collegepaeds.ac.za). 
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have less subjunctional folds compared to skeletal muscle (Spencer and Porter, 1988). The 
anatomical and physiological differences identified between EOMs and skeletal muscles have 
further been extended to a transcriptional level where differences in gene and protein expression 
patterns have been demonstrated at both synaptic and extrasynaptic regions (Soltys et al., 2008). 
However, it still remains to be elucidated why EOMs are more susceptible to certain diseases but 
not others. For example, they are spared in Duchenne’s muscular dystrophy and motor neuron 
disease yet are prominently involved in Graves’ disease and MG. In addition to altered muscle 
pathway proteins, genes involved in the immune response were also shown to have varying 
degrees of expression when comparing EOMs and skeletal muscle (Porter et al., 2001). Most 
notably, Kaminski et al (2004) showed that the complement regulator protein, decay accelerating 
factor (DAF) is expressed at a low level in the EOMs which could be contributing to their 
susceptibility to complement-mediated injury in MG.  
1.4 The role of the complement pathway in MG 
The complement pathway is a critical component of the innate immune system. It is a cascade of 
biochemical reactions composed of over 30 different serum and membrane proteins, which act 
synergistically to clear pathogens from the body and help immune cells to fight cancers and 
infections. It does this through a number of processes including cell lysis of pathogens, 
enhancement of phagocytosis and the attraction of inflammatory cells. Complement can be 
activated by three major pathways namely the alternative, lectin and classical pathways (see Figure 
1.2). The alternative pathway is spontaneously activated on cell membranes, in plasma and other 
body fluids. Antibody binding to the target antigen results in the activation of the classical pathway 
whereas the lectin pathway is triggered when mannose-binding lectin binds to the surface of target 
microorganisms. Upon activation, all three pathways ultimately result in a complement cascade 
involving the cleavage of C3 and C5 into fragments mediated by the proteolytic enzymes known as 
the C3/C5 convertases, followed by a series of activation steps and the formation of the 
membrane-attack complex (MAC), a multimeric protein complex that produces cell lysis.  
The importance of complement in MG disease pathogenesis has long been documented and 
extensive data suggests the classical pathway is responsible for AChR loss at the neuromuscular 
junctions in experimental autoimmune MG (EAMG) and MG (Kusner et al., 2008). An early study by 
Nastuk et al (1959), identified that serum from MG patients had less complement factors  
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Figure 1.2: The alternative, classical and lectin pathways are involved in the complement system. For MG, 
the classical pathway is most relevant because of its activation by the antibodies that attack the 
acetylcholine receptors. All three pathways converge on the C3 and C5 leading to their cleavage which 
results in the activation of the membrane-attack complex (MAC) causing cell lysis and membrane 
destruction.  
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than serum isolated from control individuals. Follow on studies reported that complement-fixing 
globulins from myasthenic sera bound to muscle sections (McFarlin et al., 1966) which were later 
shown to bind specifically to the neuromuscular junctions (Engel et al., 1977). The complement 
activation fragments of C3, C9 and the MAC have also been found at the degenerating postsynaptic 
neuromuscular junctions in animal models of EAMG and MG patients (Nakano and Engel, 1993; 
Sahashi et al., 1980). Furthermore, the C3 component was shown to be localised at the motor end-
plate in animals with EAMG (Sahashi et al. 1980). The assembly of the MAC was shown to cause 
damage at the postsynaptic surface of MG muscle contributing to failure of neuromuscular 
transmission (Soltys et al. 2009). Studies using EAMG models in mice showed those deficient in C4 
or C5 had less severe MG (Christadoss, 1988; Tüzün et al., 2003) while genetically modified mice 
not expressing cell-surface complement regulator proteins develop severe weakness with EAMG 
(Lin et al., 2002). Based on these and other reports it is now recognized that the consequences of 
complement-mediated damage at the neuromuscular junction as a result of autoantibody 
activation is the main effector mechanism in the pathogenesis of MG.  
1.5 Decay accelerating factor  
It is critical for the human body to tightly regulate the complement system in order to avoid 
activated autologous complement that would otherwise result in damage to self-tissues. For this 
reason a group of proteins known as complement regulatory proteins are ubiquitously expressed 
on the surface of most cell types. There are a number of complement regulatory proteins that have 
been identified in humans including: decay accelerating factor (DAF, or CD55), membrane cofactor 
protein (MCP, or CD46), complement receptor 1 (CR1, or CD35) and membrane inhibitor of cell lysis 
(MIRL, or CD59). Specifically, MCP serves to inactivate complement components C3b and C4b 
(Riley-Vargas et al., 2004), CR1 mediates the transport of immune complexes to phagocytes 
(Zorzetto et al., 2003) and CD59 acts as an inhibitor of the structuration of the complement 
membrane attack complex (Meri et al., 1990). Structurally, all the complement regulatory proteins 
contain variable numbers of complement control protein domains comprising approximately 70   
amino acid repeating motifs, also known as short consensus repeat domains. 
Hoffman was the first to describe DAF in human erythrocytes in 1969, and DAF was later isolated 
and characterised in 1982 by Nicholson-Weller et al. In humans there are two major variants of DAF 
derived from alternative splicing of the DAF gene: the first is anchored to the plasma membrane by 
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a glycosylphosphatidylinosital anchor (gDAF) (Figure 1.3) and the second is a soluble form (sDAF) 
(Medof et al., 1987). The gDAF variant is ubiquitously expressed in different cell types whereas the 
sDAF isoform is expressed at lower levels in body fluids such as tears, saliva, plasma and urine 
(Medof et al., 1987). DAF functions to regulate complement by inhibiting the assembly of and 
accelerating the degradation of pre-existing C3 and C5 convertases (Lublin and Atkinson, 1989; 
Medof et al., 1984). This prevents autologous complement activation and formation of the MAC, 
thereby protecting cells from complement-mediated injury.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Structure of the human gDAF isoform. gDAF is attached to the cell membrane via a 
glycosylphosphatidylinositol (GPI)-anchor (adapted from He et al., 2002). SCR= short consensus repeat. 
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Expression of DAF is known to be influenced by both tissue (Lin et al., 2001) and cell type (Thomas 
and Lublin, 1993). Previous studies have reported that DAF is primarily regulated at a 
transcriptional level (Thomas and Lublin, 1993) although there is evidence that tissue-specific 
factors and inflammation can influence DAF mRNA stability (Andoh et al., 2001). Moreover, DAFs 
expression can be regulated by cytokines such as IL-1, IL-6, TNF-alpha and IFN-gamma (Spiller et al., 
2000; Ahmad et al., 2003), prostaglandins (Holla et al., 2005), bacterial lipopolysaccharide 
(LPS)(Cauvi et al. 2006), and tissue-specific factors (Andoh et al., 2001). For example, endothelial 
murine Daf (equivalent to the human gDAF isoform) protein and mRNA levels were increased four-
fold above basal levels after 24 to 48 hours stimulation with TNF-α. This Daf upregulation was 
modulated by, amongst others, nuclear factor-KB (NFκB) dependent pathways (Ahmad et al., 2003). 
Apart from its role as a complement regulatory protein, DAF has other functions including 
protecting against natural killer-mediated lysis (Finberg et al., 1992), acting as a receptor for 
microorganisms and certain viruses (Pham et al., 1995), serving as a ligand for intracellular adhesion 
by primarily interacting with CD97 leukocytes (Hamann et al., 1996) as well as a negative modulator 
of T-cell immunity (Liu et al., 2005).  
1.6 Problem identification 
Previously, the Groote Schuur MG clinic in Cape Town reported variations in clinical outcomes of 
MG amongst the different ethnic groups in South Africa (Heckmann et al., 2007). It has been 
observed that a subpopulation of MG patients who are African or of recent African genetic descent 
develop a severe extraocular muscle (EOM) complication (Figure 1.4) characterised by 
ophthalmoplegia (paralysis of all the extraocular muscles) and ptosis (eyelid drooping) which does 
not respond to immunosuppressive drug treatment (Heckmann et al., 2010; Heckmann et al., 
2012). Previous data from a study in our laboratory showed that a c.-198C>G single nucleotide 
polymorphism (SNP) located in the regulatory region of DAF is associated with the development of 
this treatment-resistant EOM phenotype (Heckmann et al., 2010). In this study the c.-198C>G SNP 
was identified in eight out of 136 MG patients and six out of 167 controls. All of the c.-198C>G SNPs 
were detected in individuals of African ancestry (Black and mixed ancestry) and was absent in both 
the White MG patients and controls. Overall, the c.-198C>G SNP was found to be significantly more 
associated with the African ancestry MG patients having the severe EOM phenotype (p=0.009). The 
MG subjects belonging to the Black subpopulation were more likely to develop paresis of at least 
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one EOM if they have the c.-198C>G promoter SNP. The Black MG patients with the c.-198C>G SNP 
also had increased likelihood of developing pareses of at least 5 EOMs (p <0.01). Similarly, in 
patients of mixed ancestry (M/A) the SNP was significantly associated with the development of one 
or more EOM dysfunction (p=0.022) but not with the developing five or more EOM. However, when 
the findings for the patients of African genetic-ancestry (Black and M/A) were combined, the 
likelihood of developing EOM with at least five or more dysfunctions was significantly increased in 
the patients with the SNP (p=0.009). None of the White MG subjects had the c.-198C>G. The same 
study also established that the c.-198C>G SNP inhibits DAF upregulation in response to immune 
stimuli such as LPS. Using a bioinformatics approach this SNP was shown to result in the potential 
gain of an NFkB binding site and a loss of a Sp1 binding site (Heckmann et al., 2010). These binding 
sites may therefore be involved in mediating the LPS-induced influence on DAF expression.  
 
 
 
 
 
 
 
Figure 1.4: Photograph of MG patient displaying the treatment-resistant extraocular muscle phentotype 
(with permission from the patient) (Heckmann et al., 2007). 
 
 
1.7 Sp1 and NFκB influence on DAF expression 
The transcription factor Sp1 is ubiquitously expressed in the nuclei of all cells and is regarded as a 
house-keeping transcription factor that regulates target gene transcription by binding to Sp1-
binding sites (Brivanlou and Darnell, 2002). In a murine model Daf was reported to have several Sp1 
transcription binding sites in its regulatory region that regulate both its constitutive expression as 
well as LPS-induced expression (Cauvi et al., 2006 ). Interestingly, in the same study the Sp1 site lost 
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in the human c.-198C>G SNP was shown to not influence constitutive expression of either Daf or 
LPS-induced Daf upregulation. Sp1 binding sites have been found to be recognised by transcription 
factors other than Sp1 and indeed, Sp1 binding sites are often found in the regulatory region of 
NFκB-regulated genes (Hirano et al., 1998). Interestingly, it has previously been reported that 
functional coupling exists between Sp1 and NFkB, as Sp1 was shown to bind with high affinity to a 
subset of NFkB binding sites (Hirano et al., 1998). 
The NFkB/Rel family of transcription factors are highly conserved and play critical roles in a wide 
range of physiological and pathological processes. In particular, NFkB serves an important role in 
the immune system by regulating both innate and immune responses (Hayden et al., 2006). The 
subunits of NFkB/Rel family of transcription factors, including p65, p50, p52, RelB and c-Rel, form 
various homo- and heterodimers that translocate to the nucleus, bind DNA thereby regulating 
target gene transcription. Even small differences in NFkB binding sites have been reported to favour 
certain dimer combinations which further can induce differences in gene regulation (Hayden and 
Ghosh, 2004). While there is limited information showing the effect of NFkB on DAF expression, 
NFkB has been shown to indirectly increase murine Daf expression via TNF-α in vascular endothelial 
cells (Ahmad et al., 2003). 
1.8 MG drug treatments 
To date there is no cure for MG and treatment approaches include symptomatic therapy and often, 
in addition, the administration of immunosuppressive agents. In the 1930’s the first rational 
treatment of MG began when Mary Walker noticed that MG symptoms were similar to that of 
curare poisoning (Walker, 1935). She administered the physostigmine drug, an anticholinesterase, 
and patients showed a rapid improvement in response to treatment. Several decades later the 
finding that MG had an autoimmune etiology (Nastuk et al., 1959; Simpson, 1960) prompted the 
use of immunosuppressive drugs. Today, corticosteroids and other immunosuppressive drugs 
constitute standard treatment for MG patients not responding to symptomatic treatment.  
Presently, symptomatic treatment using acetylcholinesterase inhibitors include neostigmine or 
pyridostigmine. These drugs target the hydrolytic enzyme acetylcholinesterase that usually 
regulates levels of acetylcholine by rapidly degrading it. Often MG symptoms respond to these 
anticholinesterases which block the active site of acetylcholinesterase so the enzyme can no longer 
break down the acetylcholine molecules before they reach the postsynaptic membrane receptors. 
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In MG there are too few functional acetylcholine receptors so with the acetylcholinesterase 
blocked, the efficiency of acetylcholine binding to these receptors is improved. If MG is severe, in 
that there are too few AChRs to “translate” the signal at the endplate, then the focus of the 
treatment shifts to immunosuppressive management of this antibody-mediated disease. As MG is a 
disease that may fluctuate in severity, the ultimate goal of MG therapy is to reverse the symptoms 
of the disease, achieve remission and maintain this state. The immunosuppressive drugs that are 
used to reverse MG symptoms include prednisone, cyclosporin A, azathioprine and methotrexate. 
1.8.1 Prednisone 
Prednisone (or prednisolone) is a corticosteroid (or glucocorticoid) drug that is the first-line 
immunosuppressive therapy in MG (Gilbert et al. 2007). The drug’s potent anti-inflammatory, 
immunosuppressive and anti-allergic actions have led to its extensive use as a treatment in a 
variety of diseases for over 60 years. Treatment strategies using corticosteroids usually begin with 
administering a high dose of the drug; however for MG patients, they are initially prescribed low 
doses in the range of 10-20 mg prednisone per day. Generally, if patients are experiencing bulbar or 
respiratory symptoms they are first pre-treated with plasma exchange therapy which decreases the 
risk of increased weakness that is often experienced with corticosteroid treatment.  
Extensive research has given an insight into the complexities of the mechanism of action of 
corticosteroids. Broadly, their anti-inflammatory properties are mediated by the repressive effect 
the drug has on multiple inflammatory genes encoding cytokines, chemokines, adhesion molecules, 
inflammatory enzymes, receptors and proteins. Specifically, corticosteroids are known to suppress 
inflammatory cytokines such as IL-1b, IL-2, IL-3, IL-6, IL-11 and TNF-α and chemokines such as IL-8, 
MCP-1, MCP-3 and MCP-4 which are required to attract inflammatory cells to sites of inflammation. 
They are also known to play a role in increasing expression of anti-inflammatory proteins. However, 
the pathways targeted by the drug that result in these beneficial effects have yet to be fully 
elucidated. 
The beneficial effects of corticosteroid drugs, such as prednisone, were initially thought to be 
mediated by its genomic effects such as receptor-mediated regulation of gene expression. Herein, 
prednisone rapidly diffuses across the cell membrane and then binds to glucocorticoid receptors 
(GRs) located in the cell cytoplasm, thereby activating them. Two versions of GRs are known to exist 
and are a result of alternative splicing. The GRα form binds the corticosteroids, whilst the less 
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expressed GRβ form is not activated by corticosteroids but is able to bind to DNA (Lu and Cidlowski, 
2004). Inactive GRs are bound to various inhibitory proteins and in addition, 90 kDa heat shock 
protein (hsp90) that acts as a chaperone thereby preventing nuclear translocation (Barnes, 1998). 
Upon activation by prednisone, hsp90 dissociates allowing the GR-corticosteroid complex to 
translocate into the nucleus. Homodimers consisting of two GR-corticosteroid complexes form in 
the nucleus which act as transcription factors by binding to glucocorticoid response elements 
(GREs) in the 5’ regulatory region of target genes that are responsive to corticosteroid treatment 
(Barnes, 1998) (Figure 1.5). This binding usually results in activation of the gene (trans-activation); 
however, negative GRE binding sites are also known to exist which repress the associated genes 
(cis-represion) (Dostert and Heinzel, 2004).  
Past research has highlighted that many of the genes repressed or activated by glucocorticoid 
drugs, such as prednisone, do not contain GREs in their regulatory regions. This led to the discovery 
that glucocorticoids can regulate inflammatory gene expression by various indirect mechanisms. 
For example, in the case of the potent pro-inflammatory transcription factor, NFκB, glucocorticoids 
have been shown to upregulate the expression of its inhibitor, IκBα, thereby preventing its 
translocation to the nucleus (Scheinman et al., 1995). Furthermore, it was suggested by Mukaida et 
al (1994) that prednisone inhibits NFkB-driven gene activation by binding and sequestering it and 
thus preventing NFkB binding to DNA. More broadly, prednisone is known to have a complex effect 
on multiple signal transduction pathways including an inhibitory effect on c-Jun N-terminal kinases 
(JNK) which are necessary for the activation of NFkB (Caelles et al., 1997). Lastly, corticosteroids are 
thought to inhibit NFkB by increasing the levels of glucocorticoid-induced leucine zipper protein, a 
known inhibitor of NFkB (Barnes, 1998). All these mechanisms prevent the increase in inflammatory 
gene expression by NFkB, and are a result of the glucocorticoids acting upstream of NFkB binding. 
However, there are reports that glucocorticoids influence chromatin remodelling mechanisms  
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Figure 1.5: Corticosteroid mechanism of action. Corticosteroids such as prednisone rapidly 
diffuse across the cell membrane and bind to glucocorticoid receptors (GR) which are complexed 
with the 90 kDa heat shock protein (hsp90). Upon ligand binding, GR dissociates from hsp90 and 
translocates to the nucleus, where it binds as a dimer to a glucocorticoid response element 
(GRE) located within the promoter of target genes (adapted from Lee, 2007). 
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downstream of NFkB-DNA binding (Hart et al., 2000). Specifically, activated glucocorticoids have 
been shown to stop expression of inflammatory genes by reversing the unwinding of DNA (Ito et al., 
2000). These diverse mechanisms further highlight the broad regulatory effects that corticosteroids 
have on gene expression.  
Research conducted over the last two decades, has also revealed the post-transcriptional actions of 
glucocorticoids. For example glucocorticoids are known to have a regulatory effect on mature 
cytoplasmic mRNA stability thereby affecting protein synthesis. It is known that the expression 
levels of certain inflammatory proteins are regulated at an mRNA level (Anderson et al., 2004). This 
is mediated by adenine-uracil rich elements (ARE) in the 3’-untranslated regions (3’ UTR) of the 
genes where proteins, such as human antigen R (HuR), bind to and are thought to stabilize the 
mRNA transcripts (Dean et al., 2004). It is suggested that glucocorticoids may inhibit the proteins 
that stabilise mRNA thereby increasing the rate of mRNA breakdown and reducing protein levels 
(Smoak and Cidlowski, 2006). Interestingly, the 3’ UTR of DAF is known to harbour an ARE and 
thereby potentially affecting mRNA stability (Gray et al., 2010).  
Overall, much remains to be understood regarding the precise molecular mechanisms by which 
prednisone mediates its potent anti-inflammatory and immunosuppressive effects. Clinically, 
adverse side-effects associated with prednisone such as adrenal suppression and hyperglycaemia 
necessitates the use of low doses or additional steroid-sparing immunosuppressant’s. In MG 
treatment regimens, the steroid-sparing agents which are commonly used include azathioprine, 
cyclosporine A, methotrexate (all used in this thesis) and mycophenolate mofetil (Heckmann et al., 
2007; Heckmann et al., 2011).  ` 
1.8.2 Cyclosporin A 
Cyclosporin A (CsA), isolated from the fungus Hypocladium inflatum gams, was found by Borel et al 
(1976) to have potent immunosuppressive properties. Since its discovery, CsA has been used 
extensively for the prevention of organ transplant rejection. The molecular mechanisms of its 
immunosuppressive actions have mostly been investigated in T-cells in which it was initially shown 
to inhibit T-cell activation and also prevent certain B-cell responses (Klaus and Hawrylowicz, 1984).  
T-cell activation requires both a signal from the T-cell receptor and a co-stimulatory signal involving 
CD28 and CD80 on T-cells. The mechanism by which CsA inhibits T-cell activation by these signals 
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involves the inhibition of cytoplasmic protein calcineurin, a serine-threonine phosphatase which is 
activated by calcium (Dolmetsch et al., 1997). Once in the cell, CsA binds to ubiquitously expressed 
cyclophilins in the cell cytoplasm; thereafter, this complex binds to and inhibits calcineurin which is 
known to be involved in T-cell signalling pathways necessary for gene expression and biological 
responses to external stimuli such as foreign antigens (Stankunas et al., 1999). In the absence of 
CsA, calcineurin is known to dephosphorylate nuclear factor of activated T-cells (NFAT) family 
members allowing their translocation into the nucleus and therefore their regulation of gene 
expression (Ho et al., 1996). The CsA-cyclophilin complex inhibits calcineurin by suppressing its 
phosphatase activity and thus preventing its activation of NFAT and consequently activation of 
NFAT regulated genes which include the cytokines IL-2 and IL-4. This inhibition of the 
calcineurin/NFAT pathway is one of the mechanisms by which CsA is thought to mediate its 
immunosuppressive actions as IL-4 is required for B-cell help while IL-2 is necessary for T-cell 
proliferation (Rao et al., 1997). 
Apart from the inhibition of the calcineurin/NFAT pathway by CsA, studies have indicated that CsA 
influences the mitogen-activated protein kinase (MAPK) signalling pathway by specifically blocking 
JNK and p38. When T-cells are activated by ligand binding of both T-cell and CD28 costimulatory 
receptor, CsA was shown to prevent activation of JNK and p38 signalling pathways (Su et al., 1994; 
Matsuda et al., 1998). Importantly, activated JNK and p38 together with ERK signalling pathways 
are known to activate transcription factors such as AP-1 and NFκB. Therefore, the downstream 
inhibition of AP-1 and NFκB activation contributes to CsA’s anti-inflammatory properties. In 
addition, there is evidence suggesting CsA may also have inhibitory effects upstream of the JNK and 
p38 signalling pathways (Matsuda et al., 1998). 
There is a paucity of information on the effect of CsA treatment on DAF expression. A study using 
human endothelial cells, found that initially DAF was upregulated by vascular endothelial growth 
factor (VEGF) thereby protecting against complement-mediated injury. However, this VEGF-induced 
activation of DAF was suppressed after CsA treatment (Mason et al., 2004). Importantly, CsA 
treatment alone had no effect on basal expression of DAF in these cells. In an additional study using 
a kidney endothelial cell model, CsA was shown to directly increase both DAF and CD49 expression 
(Kim et al., 2007). The effects of CsA treatment on DAF expression therefore suggest potential cell-
type specific effects. Interestingly, CsA has been shown to increase the synthesis of TGF-β in vitro 
and in vivo (Li et al., 1991; Khanna et al., 1994). Moreover TGF- β is known to upregulate DAF on 
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primary cultures of orbital fibroblasts (Cocuzzi et al., 2001). However, no studies have as yet 
investigated the effect of CsA on DAF expression in a myofibroblast lineage.  
Despite CsA’s popularity as an immunosuppressive drug to prevent organ transplant rejection, its 
extreme potency leads to severe side effects such as nephrotoxicity, neurotoxicity and 
hepatotoxicity (Kahan, 1989; Hojo et al., 1999). However, the beneficial effects of CsA include its 
relatively short onset of action of  between one and three months compared with the more delayed 
effects of the other steroid-sparing agents discussed below.  
1.8.3 Azathioprine 
Azathioprine (AZA) is one of the oldest immunosuppressive drugs which has been used for almost 
60 years primarily to prevent organ transplant rejection. Other diseases which commonly use AZA 
as a treatment include rheumatoid arthritis, hematologic malignancies and inflammatory bowel 
disease.  
Azathioprine is a synthetic purine and falls under the thiopurine drug classification. Once ingested, 
AZA is readily absorbed by the gut and converted to its active metabolite form 6-mercaptopurine 
(6-MP). Moreover 6-MP is further metabolized by three competing pathways, of which only one 
pathway produces an active compound known as 6-thioguanine (Belgi and Friedmann, 2002).  The 
drug’s mechanism of action, although not yet well defined at a molecular level, was initially 
attributed to its inhibitory effect on purine nucleotide biosynthesis (Lennard, 1992). Initial reports 
suggested the active compound 6-thioguanine is randomly incorporated into DNA which thus 
effects cells with high proliferation rates, such as T-cells, thereby suppressing them (Lennard, 1992). 
However, the doses of AZA used in these early studies were far higher than the dosage given to 
inflammatory bowel disease patients (Cuffari et al., 1996). Later an in vitro study showed clinically 
relevant doses of AZA were able to mediate significant apoptosis of T lymphocytes (Tiede et al., 
2003). Furthermore, a new mechanism was described in which AZA targets the small GTPase, Rac1 
resulting in apoptosis seen in T lymphocytes. Overall, small GTPases have roles in a range of cellular 
processes such as cell growth and differentiation (Atreya and Neurath, 2009). The AZA metabolite, 
6-thioguanine was shown to bind to Rac1 (Tiede et al., 2003) preventing interaction with its 
guanosine exchange factor, VAV, which ultimately reduced Rac1 activation. This prevented Rac1 to 
interact with its target genes including, MEK, NFκB and Bcl-xL which led to a mitochondrial pathway 
of apoptosis (Tiede et al., 2003).  
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Specifically in the case of MG patients, the beneficial effects of AZA also include the ability to 
reduce anti-AChR antibody levels (Mantegazza et al., 1988). Although AZA has an apoptotic effect 
on T-cells, the drug appears not to influence the release of cytokines from dividing or non-dividing 
T-cells which have not yet undergone T-cell mediated apoptosis (Ben-Horin et al., 2009). Some have 
suggested this may be the reason why AZA has a delayed clinical response which may take up to 15 
months before steroid-sparing effects are seen.  
1.8.4 Methotrexate 
Methotrexate (MTX) is a potent anti-inflammatory and immunosuppressive agent which is regarded 
as the gold standard for rheumatoid arthritis treatment. The drug is a folic acid antagonist that is 
known to inhibit both purine and pyrimidine synthesis. These effects are mediated by MTX 
inhibiting enzymes such as dihydrofolate reductase, thymidylate synthase and 5-aminoimidazole-4-
carbox-amide ribonuleotide (AICAR) transformylase which all ultimately lead to inhibition of purine 
and pyrimidine biosynthesis. This therefore greatly inhibits cells with high proliferation rates such 
as T-cells. Other molecular mechanisms that contribute to the drugs potent anti-inflammatory 
effects include promotion of adenosine release that results in adenosine-mediated suppression of 
inflammation (Cronstein, 2005).  
MTX is usually administered to patients either orally or intramuscularly, and is readily absorbed by 
cells after which it rapidly undergoes polyglutamation (MTXGlu). The MTXGlu then inhibits AICAR 
transformylase, resulting in the accumulation of AICAR transformylase that inhibits AMP 
deaminase. This ultimately leads to the release of intracellular adenine nucleotides and adenosine 
into the extracellular matrix (Tian and Cronstein, 2007). The extracellular AMP, ADP and ATP are 
then dephosphorylated to adenosine (Tian and Cronstein, 2007) which is able to bind to specific 
adenosine receptors expressed on the cell membrane. The mechanisms by which adenosine 
mediates anti-inflammatory responses is still largely unknown. However, in a mouse model of 
rheumatoid arthritis, the anti-inflammatory effects of MTX were completely reversed when the 
mice were treated with the adenosine receptor antagonists, theophylline and caffeine (Montesinos 
et al., 2007). An additional mechanism by which MTX mediates its anti-inflammatory effects is 
thought to be through inhibition of NFκB. A study by Majumdar and Aggarwal (2001) in Jurkat T-
cells and fibroblasts, suggested that MTX inhibits IκBα phosphorylation and degradation, which in 
turn, prevents NFκB activation.  
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The effects of MTX on purine and pyrimidine biosynthesis contribute to its potential toxicities which 
may include bone marrow suppression, liver toxicity and stomatitis. However, patients are 
generally administered folic acid that has been shown to help prevent MTX-associated toxicities. 
The low cost of the drug and its anti-inflammatory effects has led to its use in MG treatment in 
South Africa. Preliminary data suggests the drug is an effective steroid-sparing agent in MG 
(Heckmann et al., 2011). 
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1.9 Objectives and aims 
The broad objective of this study was to explore the molecular mechanism(s) that govern 
extraocular muscle treatment-resistance in a subset of myasthenia gravis patients of African origin. 
This was achieved by the following specific aims: 
1. To determine the effect(s) of prednisone, the first line immunosuppressant therapy for MG 
treatment, on wild-type versus C>G DAF expression. 
2. To investigate the effect(s) of the steroid-sparing drugs cyclosporin A, azathioprine and 
methotrexate alone or in combination with prednisone on wild-type versus C>G DAF 
expression. 
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CHAPTER 2: Materials and Methods 
 
2.1 Generation of Epstein-Barr Virus transformed B lymphocytes 
Lymphoblastoid cell lines were derived from healthy non-MG patient control individuals (n=3 and 
expressing WT DAF) or MG patients (n=6 and expressing C>G DAF) attending the University of Cape 
Town MG clinic. Consent for the experimental use of the lymphocytes was obtained from the 
control individuals or MG patients. Lymphoblastoid cell lines were established by transforming 
lymphocytes from peripheral blood using Epstein-Barr virus (EBV) described below. Briefly, isolated 
peripheral blood was spun at 3000 x rpm using a bench top centrifuge (Centrifuge 5810R, 
Eppendorf, Germany) for 5 mins at room temperature (RT). The buffy coat, containing leucocytes 
and platelets, and serum layers was gently removed from the centrifuged blood and added to a 
layer of Histopaque (Sigma, USA) which enables separation of cells based on a density gradient. The 
mixture was spun at 3500 x rpm for 20 mins to collect the red blood cells at the bottom of the tube 
leaving a serum layer at the top containing the lymphocytes and platelets. The serum was carefully 
removed and added to a fresh tube and washed twice with culture media, containing Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Appendix A) + 10% heat-inactivated foetal calf serum (FCS) 
(Gibco, UK)  and 1% Penicillin-Streptomycin (P/S) (Appendix A), and then incubated in 5 mls of EBV 
containing culture media.   
The EBV was obtained by culturing B95.8 cells, a marmoset blood leukocyte line that releases high 
titres of transforming EBV, under acidic conditions. Media was collected and transferred to a 50 ml 
conical tube, then spun down at 400 x g for 10 mins. The supernatant was removed and filtered 
through a 0.22 μm filter. The filtrate containing the EBV particles without any donor cells was mixed 
with an equal amount of fresh culture medium, stored at 4°C for a maximum of 6 months and was 
used to transform blood lymphocytes. 
To obtain only B-lymphocyte cell lines, lymphocytes obtained as described above were cultured for 
3 days at 37°C in EBV media containing phytohaemagglutinin (Welcome Reagents Ltd, UK), which 
kills contaminating T lymphocytes. Transformed B lymphoblasts were monitored twice a week and 
the media changed depending on the cell growth. 
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2.2 Genotype sequencing of lymphoblasts 
The genomic DNA of healthy control or MG patients was screened to ensure lymphoblast cell lines 
with the correct genotype, WT decay accelerating factor (DAF) or c.-198C>G SNP (C>G SNP) DAF, 
was used for the duration of this study.  
2.2.1 Isolation of genomic DNA from lymphoblasts 
Genomic DNA was extracted from lymphoblastoid cells generated from healthy control individuals 
or MG patients, using the QIAamp DNA Blood Midi Kit (Qiagen, USA) as per manufacturers’ 
instructions. Briefly, lymphoblasts were pelleted using a benchtop centrifuge (Centrifuge 5810R, 
Eppendorf, Germany) at 1000 x rpm for 5 mins at RT. The culture media-infused supernatant was 
removed and the pellet washed twice in sterile 1 x phosphate buffered saline (PBS) (Appendix A) by 
centrifugation at 300 x g for 5 mins. Twenty microliters of Proteinase K and 200 µl AL Buffer was 
added to the cells, pulse vortexed for 15 seconds, then left to incubate at 56°C for 30 mins in a 
heating block. Following incubation, 200 µl ethanol was added to each tube and mixed by pulse-
vortexing for 15 seconds followed by brief centrifugation. The mixture was then applied to a spin 
column and centrifuged at 13 000 x rpm for 1 min at RT. The column was placed into a clean 
collection tube and 500 µl AW 1 Buffer was added to the column and centrifuged for 1 min at 
13 000 x rpm at RT. Again the column was inserted into a clean collection tube, 500 µl AW 2 Buffer 
was added and the column centrifuged for 3 mins at 12 000 x rpm at RT. The flow through was then 
discarded and the column centrifuged for 1 min at 12 000 x rpm. Finally the column was inserted 
into a fresh 1.5ml microcentrifuge tube, 100 µl AE buffer added to the top of the column, and left 
to incubate at RT for 10 mins. Thereafter, the DNA was collected in the microcentrifuge tube by 
centrifugation at 12 000 x rpm for 1 min and stored at -20°C. 
2.2.2 Measuring DNA concentration 
The concentration of extracted DNA was measured using a NanoDrop ND-1000 UV-visible 
spectrophotometer (NanoDrop Technologies, USA). The NanoDrop ND-1000 3.3 software (Coleman 
Technologies Inc., USA) displays the concentration in ng/μl and an estimation of the purity of DNA 
is assessed by 260/280 ratio. A ratio of 1.8-2.0 is accepted as pure for DNA.  
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2.2.3 Conventional polymerase chain reaction (PCR) 
To screen for the C>G SNP in the DAF gene, PCR was performed under the following conditions: 
initial denaturation at 94°C (5 mins) followed by 25 amplification cycles comprising denaturation at 
94°C (30 seconds), annealing at 60°C (30 seconds), extension of 72°C (30 seconds), followed by a 
final extension at 72°C (7 mins) in a 2720 Thermal Cycler (Applied Biosystems, USA). The forward 
and reverse primers were designed by Dr Robea Ballo and were specifically designed to amplify the 
region of DNA in the DAF gene where the c.-198C>G SNP is situated. Table 2.1 shows the optimised 
PCR reaction mixture. 
Table 2.1: PCR reaction mixture for DAF gene amplification. 
Reagent Amount 
Template DNA  100 ng/µl 
Forward Primer (20 µM) 1 µl 
Reverse Primer (20 µM) 1 µl 
2 x Failsafe Buffer (Epicentre Biotechnologies, 
USA) 
7.5 µl 
GoTaq DNA polymerase (Promega, USA) 0.2 µl 
Nuclease free H2O 4.3 µl 
 
2.2.4 Agarose gel electrophoresis 
The size of the amplified PCR product was checked by electrophoresis on a 2% agarose gel 
(Appendix A). Once the 2% gel solution was solidified, the gel comb was removed from the casting 
platform and placed in the electrophoresis tank (OMEG Scientific, SA) filled with 1 x TBE buffer 
(Appendix A). A total volume of 8 μl of sample was loaded per well containing 5 μl of PCR product 
mixed with 3 μl of agarose loading dye. In this study, the loading dye was spiked with the 
fluorescent stain, SYBR gold (Invitrogen, USA) in the ratio 1:2000 to allow for visualisation on a UV 
transilluminator (Spectroline Model TR-312A Transilluminator, USA). A 100 bp molecular weight 
marker (Appendix C) was also loaded onto the gel.  
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2.2.5 Sequencing 
Sequencing of PCR products was performed by Inqaba biotech (SA). The sequences obtained were 
confirmed manually and analysed for any changes by aligning them with the known reference 
sequence using the Clustal Alignment facility in BioEdit version 7.0.0 (data not shown).  
2.3 Amplification of plasmid constructs 
The DAF promoter region (-724 to +80) cloned as a Bgl II and Hind III fragment in the pGL3 firefly 
luciferase reporter vector was kindly donated by Ray DuBois (Holla et al., 2005). Using the WT DAF 
reporter construct as a template, site directed mutagenesis was performed to mutate the C at 
position -198 to G (performed by Dr Huajiang Teng, UCT). 
2.3.1 Making competent cells 
DH5α E.coli cells were inoculated into 5 ml of Luria Broth (LB) (Appendix A) and incubated overnight 
at 37°C with shaking. One millilitre of this culture was then used to inoculate 100 ml of LB and cells 
were grown for 2 to 3 hrs until cell growth reached the log phase (OD600nm=0.5-0.8). Cells were 
centrifuged at 3000 x g for 10 mins at RT (Centrifuge 5810R, Eppendorf, Germany); the bacterial 
pellet resuspended in 100 mM ice-cold calcium chloride (CaCl2) solution and incubated on ice for 1 
hr. Following centrifugation at 3000 x rpm for 1 min, the supernatant was discarded and 1 ml of ice-
cold CaCl2 was used to resuspend the pellet. CaCl2 permeabilises the cell wall of the bacteria to 
allow entry of foreign DNA but this causes the cells to be very fragile and care was taken in 
successive processes so as not to damage the cells. Finally 100 μl of competent cells were either 
used immediately for DNA transformation or they were frozen in autoclaved glycerol at -80°C for 
long term storage. 
2.3.2 Transformation 
To 100 μl of competent cells, 1 μl of DNA plasmid solution was added and then incubated on ice for 
10 mins. Cells were heat-shocked at 42°C for 2 mins, to allow the bacteria to take up the DNA 
constructs. Cells were then incubated on ice for 2 mins, after which 300 μl of antibiotic-free LB was 
added and the cells incubated at 37°C for 30 mins with gentle shaking. Following incubation, 50 μl 
of each transformation reaction was plated onto LB-Amp agar plates. Plates were incubated at 37°C 
with the agar side down for 20 mins, then inverted with the agar side up and left to grow overnight. 
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A negative control plate containing un-transformed competent cells was included. No growth 
should be seen on the negative control plate as only cells carrying the ampicillin resistance-
containing vector DNA should survive. 
2.3.3 Ampicillin agar plates 
All plasmids used in this study carried the Ampicillin (Amp) resistance gene. Amp (50 μg/ml) was 
added to 1.5% bacterial agar (prepared in LB) which was poured into 10 cm dishes to a volume of 
20 ml per dish. The agar was allowed to set at RT and then dried overnight at 37°C. 
2.3.4 Large scale preparation of plasmid DNA 
To screen for bacterial colonies carrying the WT or C>G DAF reporter construct, colonies were 
selected from the LB-Amp agar plates and used for the large-scale preparation of plasmid DNA. The 
bacterial colonies selected were removed with a sterile pipette tip, inoculated into 3 ml LB medium 
containing Amp and incubated overnight at 37°C with shaking. One millilitre of overnight culture 
was used to inoculate 250 ml LB-Amp broth. The PureYield Maxiprep System kit (Promega, USA), 
which makes use of a silica-membrane column filtration, was used following the manufacturers’ 
instructions to isolate high quality plasmid DNA. Briefly, cells were collected by centrifugation at 
5000 x g for 10 mins. The pelleted cells were resuspended in 12 mls of supplied Cell Resuspension 
Solution. To the above solution, 12 ml of supplied Cell Lysis Solution was added; the solution was 
mixed gently by inverting the tube 3-5 times and incubated at RT for 3 mins. This solution 
hydrolyses the bacteria and disrupts the cell membrane. The reaction was neutralised by adding 
Neutralisation Solution and inverted several times to completely precipitate the cell debris. 
Thereafter, the lysate was centrifuged at 7000 x g for 30 mins at RT in a fixed-angle rotor to pellet 
the bulk of the cellular debris. DNA was isolated from the lysate by being passed through a filtration 
column using a vacuum manifold. DNA becomes trapped on a binding membrane that is washed 
with an ethanol-containing Column Wash. Following this, the DNA was eluted in 200 µl of nuclease-
free water. The DNA concentration was checked using the NanoDrop ND-1000 UV-visible 
spectrophotometer (NanoDrop Technologies, USA) together with the NanoDrop ND-1000 3.3 
software (Coleman Technologies Inc., USA). The integrity of the DNA isolated was additionally 
checked by electrophoresis on a 2% agarose gel as previously described in section 2.2.4. 
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2.4 Maintenance of cells in culture 
Lymphoblast (described in section 2.1), COS-7 (Green monkey epithelial kidney) and C2C12 (mouse 
myoblast) cells were cultured in DMEM supplemented with 10% heat inactivated FCS and 1% P/S 
antibiotics in a 37°C (95% air, 5% CO2, 65% humidity). C2C12 cells were allowed to differentiate by 
switching from growth medium (DMEM + 10% FBS + 1% P/S) to differentiating medium (DMEM 
supplemented with 2% Horse serum and 1% P/S). All cultures were routinely subjected to 
mycoplasma tests and only mycoplasma free cells were used in experiments. 
2.4.1 Mycoplasma test 
Cells grown on a coverslip in antibiotic-free media for 2-3 days were fixed in a 1:3 mixture of glacial 
acetic acid and methanol for 5 seconds, washed briefly with water to remove the fixing solution and 
then air-dried at RT for 5 mins. Once dried, the DNA was stained with Hoechst 33258 (0.5 μg/ml) 
(Appendix C) for 6 mins, washed briefly with water to remove excess stain and then mounted on a 
slide with mounting fluid at pH 5.5 (Appendix A). The cells were viewed immediately by 
fluorescence microscopy under the DAPI filter. Mycopl sma negative cells stained positive with 
Hoechst 33258 only in the nucleus, while cells infected with mycoplasma showed staining in both 
the nucleus and cytoplasm. 
2.5 Drug treatments 
2.5.1 MG Drug treatments 
Prednisone, methotrexate, cyclosporine A and azathioprine (all Sigma, USA) were the drugs used in 
this study. They were dissolved in specific reagents to stock concentrations (Appendix B). For 
western blotting, qRT-PCR analysis, luciferase and calcien assays cells were treated with presumed 
clinically relevant doses of the drugs for the indicated time durations. The doses for each drug used 
were: Prednisone = 0.1, 1, 3, 10, 30 and 60 μM (Ribichini et al., 2007; Wang et al., 2006); 
methotrexate = 10 and 22 μM (Fotoohi et al., 2004); cyclosporin A = 0.25 and 5 μM (Chen et al., 
2004; Düfer et al., 2001); azathioprine = 5 μM (Bobbala et al., 2009; Petit et al., 2008). 
2.5.2 Lipopolysaccharide treatment of cells 
Powdered lipopolysaccharide (LPS) (Sigma, USA), was dissolved in 1x PBS to a final working 
concentration of 10 μg/ml (Koide and Steinman, 1987) (Appendix B). For promoter and calcien 
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assays, cells were treated with 10 μg/ml LPS for 12 hrs before processing of the respective assays. 
C2C12 cells were treated with 10 μg/ml LPS for 24 hrs while for qRT-PCR and western blot analysis 
performed in lymphoblasts, cells were treated with 10 μg/ml LPS for 19 hrs. 
2.5.3 Serum treatment of cells 
Serum was isolated from blood donated by normal healthy controls (not MG patients) or 
treatment-naïve MG patients (C.-198C>G SNP not confirmed in these individuals) with consent 
granted from the respective individuals. Briefly, coagulated blood was spun at 900 x g for 15 mins at 
RT using a bench top centrifuge. Under sterile conditions the supernatant sera was transferred to 
microcentrifuge tubes and stored at -20°C. For western blot analysis and calcein assays, cells were 
treated with appropriate dilutions of sera for the indicated durations.  
2.6 Transient transfection 
Prior to performing all transfections the quality and concentration of all DNA constructs was 
confirmed by agarose gel electrophoresis (data not shown). 
COS-7 cells were transiently transfected with FuGENE HD (Roche, USA) according to the 
manufacturers’ instructions. Briefly, cells were plated at 3 x 104/ml and grown to approximately 
60% confluency in 12-well plates a day before transfection with 450 ng of either the WT or C>G DAF 
promoters cloned into a pGL3-basic firefly luciferase reporter vector. 45 ng of the pRL-TK vector 
(Promega, USA) was included in each transfection to serve as an internal control to monitor and 
standardize the transfection efficiency between samples. Exactly 1.5 μl of the transfection reagent 
diluted into 48.5 μl serum-free media (without antibiotic) was prepared at RT and allowed to stand 
for 5 mins. The diluted transfection reagent was added in a drop wise manner to the DNA, mixed 
and incubated at RT for 15 mins. Thereafter, the transfection reagent:DNA complex was added drop 
wise to the cells incubated for 6 hrs in a 37°C incubator. After incubation, transfection media was 
removed and 1 ml serum-free media (Appendix A) was added to each reaction well in the 12-well 
plate. 
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2.7 Luciferase assays 
Luciferase assays were carried out using the Dual-Luciferase Reporter (DLR) Assay System 
(Promega, USA) according to the manufacturers’ instructions. Firefly and renilla are two different 
enzymes acting on different substrates to produce a luminescent reaction. DLR enables the 
detection of the enzymatic activity of both enzymes within a single sample. Transfected cells were 
washed twice with cold 1x PBS and then lysed with 200 μl of 1x Passive Lysis Buffer by shaking at RT 
for 15 mins. Cell lysates were transferred into 1.5 ml centrifuge tubes and incubated at -80°C 
overnight. Luciferase assays were performed according to the instructions of the manufacturer and 
luciferase activity was measured using the Luminoskan Ascent luminometer (Thermo Labsystems, 
Franklin, MA, USA). Briefly, the cell lysates were thawed at RT, vortexed and centrifuged (Heraeus 
Biofuge Pico, Germany) at 13 000 x rpm for 1 min, and 10 μl of each sample was assayed 
immediately for reporter gene activity. Results obtained were normalized for transfection efficiency 
by dividing firefly readings by the renilla readings. Promoter activity was calculated as a ratio of the 
luciferase activity generated by the internal pRL-Tk vector to that obtained in the presence of the 
appropriate WT or C>G DAF expression vector. The Microsoft Excel programme was used to 
calculate the standard deviation and statistically significant differences between samples using the 
paired 2-tailed Student t test. P values of ≤0.05 were considered statistically relevant. 
2.8 Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.8.1. Total RNA extraction 
Total RNA was extracted from lymphoblasts using the High Pure RNA Isolation Kit (Roche, USA) as 
per manufacturers’ instructions. Diethyl pyrocarbonate (DEPC) treated microfuge tubes and pipette 
tips (Appendix A) were used to minimize RNA degradation during the extraction process as DEPC 
destroys RNases. The quality and concentration of RNA was determined by spectrophotometry and 
samples with an A260/A280 ratio equal to or above 1.8 were selected and stored at -80°C for 
further applications. 
2.8.2 Reverse transcription 
As RNA is easily degraded by RNAses, which are abundant in the environment, the RNA was quickly 
converted to complimentary DNA (cDNA) which is much more stable. The reverse transcriptase 
enzyme synthesizes double stranded cDNA from RNA using the reverse transcription process. The 
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mRNA was then transcribed into cDNA using the Improm-II Reverse Transcription System (Promega, 
USA) following the manufacturers’ instructions. Briefly, 540 ng of RNA was combined with 1 μl of 
Oligo (dT) primer in a total volume of 5 μl, and then heat denatured at 70°C for 5 mins followed by 
incubation on ice for a further 5 mins. Thereafter, the reverse transcription mix was added (Table 
2.2) and the mixture incubated for 5 mins at 25°C in a controlled-temperature heating block for the 
annealing process to take place and the cDNA strands allowed to extend at 42°C for an hour. The 
reverse transcriptase was then inactivated at 70°C for 15 mins and the cDNA stored at 4°C. 
Table 2.2: Components of the Improm-II Reverse Transcription System Mix. 
Reagent Volume Final Concentration 
Reagent Buffer (5x)  4 µl 1x 
MgCl2  2.4 µl 3 mM 
dNTP mix  1 µl 0.5 mM each dNTP  
Recombinant RNasin 
Ribonuclease Inhibitor  
0.5 μl  
 
20 units 
Reverse Transcriptase  1 μl  - 
Nuclease free water 6.1 μl - 
Total volume  15 µl - 
 
2.8.3. Quantitative Real-time PCR 
The Sensimix Lite kit (Quantace, UK) was used to quantify the mRNA expression levels of the target 
gene gDAF and the house-keeping gene, glucuronidase B (GUS B), following the manufacturers’ 
instructions. The forward and reverse primers used were specifically designed by Dr Robea Ballo to 
amplify the membrane-bound gDAF. The forward and reverse primers were: (5’-
GGATTCACCATGATTGGAGAGC- 3’) and (5’- TGTGCCCAGATAGAAGAC- 3’) respectively. The 
oligonucleotide primers for the house-keeping gene GUS B was obtained from Quantitect (QIAGEN, 
USA). Briefly, reagents were mixed in glass capillaries to a final volume of either 10 or 20 μl as 
shown in Table 2.3. The capillaries were sealed and then centrifuged at 3000 x rpm for 30 seconds. 
The procedure was performed in the Lightcycler machine (Roche, Switzerland) and the levels of 
fluorescence were quantified using the accompanying Light Cyler Software Version 3 (Roche, 
Germany). Cycling conditions were generally similar for the gDAF and the house-keeping gene but 
differed in the holding times in the cycling step (Tables 2.4 and 2.5). Each DNA sample was 
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quantified in duplicate and a negative control without cDNA template was run with every assay to 
assess the overall specificity. 
Table 2.3: Real-time PCR parameters used for amplification of gDAF and GUS B genes. 
Reagent gDAF GUS B 
5x Sensimix Lite (dNTPs, 15 
mM MgCl2, stabilizers)  
4 µl 2 µl 
Enzyme mix (Taq DNA 
Polymerase)  
1.5 μl  
 
0.75 μl  
 
50x SYBR green  0.4 µl 0.2 µl 
Primers (10 pmol)  
 
Forward: 0.4 μl  
Reverse: 0.4 μl  
1.5 μl of combined forward and 
reverse primers  
Sterile water  12.3 μl  4.55 μl  
cDNA  1 μl  1 µl 
Total volume  20 µl 10 µl 
 
Table 2.4: Real-time PCR optimal cyclic conditions used for gDAF. 
 Cycle number 
 
Target °C 
 
Holding time 
(mins) 
Ramp/Slope 
(°C/sec) 
Activation  1 95  10:00  20 
Cycling  
Denaturing 
Annealing  
Extension  
35  
95  
55  
72  
 
00:15  
00:30  
00:30  
 
20  
20  
20  
Melting  
Denaturing 
Annealing  
Extension  
1  
95  
65  
95  
 
00:00  
00:15  
00:00 
 
20  
20  
0.1  
Cooling  1 40  00:30  20 
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Table 2.5: Real-time PCR optimal cyclic conditions used for GUS B. 
 Cycle number Target °C Holding time 
(mins) 
Ramp/Slope 
(°C/sec) 
Activation  1 95 15:00  0 
Cycling  
Denaturing 
Annealing  
Extension  
35  
95  
55  
72  
 
00:05 
00:03  
00:05 
 
20  
20  
20  
Melting 
Denaturing 
Annealing  
Extension 
1  
95 
65 
95 
 
00:00 
00:15 
00:00 
 
20 
20 
20 
Cooling 1 40 00:30 20 
 
2.8.4 Quantification of mRNA 
To quantitate differences in mRNA levels the relative quantification method was employed. The 
change in expression was calculated using the ΔΔCt method (Pfaffl, 2001). Relative mRNA 
expression levels were normalized to GUS B for each reaction. The Microsoft Excel programme was 
used to calculate the standard deviation and statistically significant differences between samples 
using the paired 2-tailed Student t test. P values of ≤0.05 were considered statistically relevant. 
2.9 Western blotting 
Approximately 2 x 106/ml lymphoblasts and 1.5 x 105/ml C2C12 cells cultured for protein analysis 
were plated in 6 cm dishes. C2C12 cells were harvested by trypsinisation (Appendix A) whilst 
lymphoblasts were collected directly in 12 ml tubes as they grow in suspension. The respective cell 
lines were pelleted by centrifugation for 5 mins at 4000 x rpm at 4°C. The cell pellets were then 
washed with 1 ml 1x PBS and then spun at 4°C in 1.5 ml microcentrifuge tubes for 4 mins at 12 000 
x rpm.  Whole cell extracts from C2C12 and lymphoblast cells were prepared under reducing and 
non-reducing conditions respectively using RIPA buffer (Appendix A) and stored on ice for 30 mins. 
After the incubation period, cell debris was pelleted by centrifugation at 4°C at 12 000 x rpm for 20 
mins and the supernatant containing the cellular protein collected and stored at -80°C. Protein 
quantification for each cell extract was determined using the BCA Protein Assay Kit (Pierce, USA) 
with bovine serum albumin as the standard. Equal amounts of protein were loaded in each lane and 
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resolved on an 8% SDS-PAGE gel and then transferred electrophoretically to a Hybond ECL 
nitrocellulose membrane (Amersham, UK). 
After transfer, the nitrocellulose membrane was rinsed in 1x PBS/0.1% Tween (Appendix A), and 
incubated in 5% milk in 1x PBS/ 0.1% Tween (Appendix A) for 1 hr at RT with shaking. The blot was 
incubated in the appropriate primary antibodies overnight at 4°C with shaking. The primary 
antibodies and appropriate dilutions were: mouse monoclonal BRIC 216 DAF (IBGRL 9404P) (NHS, 
UK) antibody diluted 1:100, rabbit polyclonal DAF (sc-9156) (Santa Cruz Biotechnologies, USA) 
antibody diluted 1:200, monoclonal mouse anti-α-tubulin (sc-51503) (Santa Cruz Biotechnologies, 
USA) antibody diluted 1:500. All antibodies were diluted in 5% milk in 1x PBS/0.1% Tween. 
Following overnight incubation in the primary antibody, the membrane was incubated with either 
peroxidase conjugated anti-rabbit or anti-mouse at a dilution of 1:5000 in 5% milk in 1x PBS/0.1% 
Tween. The proteins of interest were detected using either SuperSignal® West Dura Extended 
Duration substrate or West pico Chemiluminescent Substrate. For both detection solutions a total 
of 1 ml of the substrates A and B detection reagents (ratio 1:1) were added to the membrane for 1 
min before the membrane was sandwiched between acetate sheets in a cassette and exposed to X-
ray film. The film was immersed in developer until bands became visible, rinsed under running 
water and immersed in fixing solution for a minimum of 4 mins. The film was rinsed in running 
water and allowed to air-dry. 
2.9.1 Stripping of nitrocellulose membrane  
Membranes probed for more than one protein were immersed in pre-heated (at 50°C) stripping 
buffer (Appendix A) for 30 mins. This was followed by 2 × 10 mins and 2 × 5 mins washes in 1x 
PBS/0.1% Tween, after which standard western blotting procedure followed. 
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2.10 Calcein assay 
Calcein-AM is a non-fluorescent compound that easily penetrates intact cellular membranes. Once 
in the cytoplasm it is cleaved by cytosolic esterases into the strongly fluorescing compound calcein. 
The degree of fluorescence emitted by calcein can be quantified and used as a direct measure of 
cell viability. In this study, lymphoblasts were plated in triplicate in 96-well plates at a concentration 
of 1 x 103/200 µl cells per well and treated with control or treatment-naïve MG patient sera for 24 
hrs with or without prednisone or LPS treatment for 24 or 12 hrs respectively. After treatments the 
assay was processed as per the manufacturers’ instructions (Trevigen Inc, USA) following the 
suspension cell protocol. Briefly, lymphoblasts were pelleted for 5 mins at 250 x g using a bench top 
centrifuge with appropriate 96-well plate adaptors (Centrifuge 5810R, Eppendorf, Germany) and 
the supernatant removed. The cell pellets were washed twice with 1x calcein buffer (Appendix A) 
and then spun at 250 x g for 5 mins. After the last wash, cells were resuspended in 1x calcein buffer 
and 2 µM Calcein-AM (Appendix A) at a 1:1 ratio then transferred to black-walled 96-well plates as 
Calcein-AM is sensitive to light. The plates were covered in foil then placed in an incubator for 30 
mins at 37°C to allow for uptake and cleavage of Calcein AM. Each assay was performed in triplicate 
and the following three controls were included; background control was subtracted from all 
measurements, a low lysis control was untreated normal cells and the high lysis control 
represented maximum calcein release after 40% triton X-100 (Sigma, USA). The results are 
presented as specific calcein release a  measure of % cytotoxicity= (test sample-low control)/(high 
control–low control) x100.  
Cell lysis was determined by inserting the 96 black-walled plates into the GloMax®- Multi 
Microplate Multimode Reader (Promega, USA) which was used to measure calcein fluorescence 
using a blue laser with a 490 nm excitation filter and a 520 nm emission filter. The fluorescence 
generated was used as a direct measure of cell viability.  
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Chapter 3: Results 
We have previously identified myasthenia gravis (MG) patients of African or recent African ancestry 
that have an increased risk of developing a treatment-resistant severe extraocular muscle 
phenotype at Groote Schuur Hospital, Cape Town (South Africa). Furthermore, data generated in 
our laboratory showed (1) a significant association between the above myasthenics and a 
functional C>G SNP in the regulatory region of decay accelerating factor (DAF) and (2) that this C>G 
SNP prevented DAF upregulation in response to lipopolysaccharide (LPS)-induced immune stress. 
On the basis of these observations we hypothesized that those MG patients with the C>G SNP are 
treatment-resistant because they have an inadequate DAF response which may be aggravated by 
standard MG drug therapies. Therefore, the first aim of this study was to determine the effect of 
prednisone on wild-type (WT) and C>G DAF expression. Prednisone was selected because in clinical 
practice it is the first-line drug used for MG treatment. Due to the side effects of prednisone, 
additional immunosuppressive drugs are administered as steroid-sparing agents for long term 
control of MG. The second aim of this study was therefore to determine the effect(s) of these 
steroid-sparing drugs alone or in combination with prednisone on WT and C>G DAF expression.  
 
3.1 Effect of prednisone on WT versus C>G DAF expression  
3.1.1 Prednisone post-transcriptionally represses C>G DAF and not WT DAF 
Wild-type (WT) and C>G DAF1 lymphoblasts were treated with 0.1, 1, 3 or 60 µM doses of 
prednisone for 24 hrs or with LPS (10 µg/ml) for 19 hrs. The various doses of prednisone were 
chosen based on similar concentrations used in published studies (Ribichini et al., 2007; Wang et 
al., 2006). Total RNA was isolated, reverse transcribed into cDNA and DAF mRNA expression 
quantified by qRT-PCR. Levels of DAF mRNA were determined using the standard curve and relative 
quantification method (Wong and Medrano, 2005). Table 3.1 shows the average fold activation, 
compared to untreated control cells, from three experiments each performed in duplicate. As 
shown previously by our group in response to LPS-induced immune stress, WT DAF mRNA levels 
increased by almost 2-fold, whereas C>G DAF mRNA levels were repressed by 1.4-fold compared to 
their untreated controls (Heckmann et al., 2010). Both WT and C>G DAF mRNA levels remained 
                                                          
1
 Nomenclature used to describe human decay-accelerating factor  
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basal in response to 0.1 or 3 µM prednisone and increased, although not significantly, after 1 or 60 
µM prednisone treatment. Taken together these results suggest that at an mRNA level, in response 
to a range of prednisone doses, the C>G SNP does not induce a differential regulatory effect when 
compared to WT DAF mRNA expression. Furthermore, prednisone treatment, irrespective of WT or 
C>G DAF, does not appear to have a regulatory effect on DAF mRNA expression when compared to 
the respective untreated control cells as the results were not significantly different.  
To confirm that prednisone does not regulate DAF mRNA levels at a transcriptional level, luciferase 
reporter assays were performed. Here, COS-7 cells were transfected with 900 ng of the firefly 
reporter driven by either the WT or C>G DAF promoters. COS-7 cells were used in these assays as 
they readily take up foreign DNA. The renilla luciferase construct was included in all experiments as 
an internal control for measuring transfection efficiency. Cells were cultured post-transfection for 
24 hrs and treated with LPS (10 µg/ml) for 12 hrs or 0.1, 1, 3 or 60 µM prednisone for 24 hrs before 
extracts were assayed for firefly and renilla luciferase activity using the dual-luciferase assay 
system. The result of pooled data from two or three transfection experiments each performed in 
duplicate is shown in Table 3.1. The treatment of LPS had no effect on WT or C>G DAF promoter 
activity; a previous study also found that COS-7 cells do not respond to LPS treatment (Veal et al., 
2004). Both the 0.1 and 1 µM doses of prednisone had no significant effect on either the WT or C>G 
DAF promoter activity compared to their untreated controls. However, unlike C>G DAF promoter 
activity which remained basal, WT DAF promoter activity significantly increased by approximately 
1.3-fold in response to 3 or 60 µM doses of prednisone. The results do not match those achieved at 
an mRNA level and this could reflect differences in the regulation of the endogenous gene 
compared to the in vitro promoter system in response to the drug. Furthermore, there may be 
differences in the cell-type specific responses to the drug.  Overall, these data suggest that the 
higher 3 and 60 µM doses of prednisone differentially regulates WT and C>G DAF promoter activity. 
The lack of effect of prednisone on WT and C>G DAF mRNA levels seen above may not necessarily 
reflect protein levels which can also be regulated post-translationally. Therefore, we next 
investigated the effect of prednisone on endogenous DAF protein levels in both WT and C>G DAF 
lymphoblasts. Protein was extracted from the respective lymphoblasts 24 hrs post-treatment with 
0.1, 1, 3 or 60 µM doses of prednisone, or with LPS (10 µg/ml) for 19 hrs, and subjected to western 
blot analysis using the BRIC 216 monoclonal antibody (IBGRL, UK) to human DAF as well as an 
antibody to tubulin which was used as a loading control. Unfortunately, due to technical difficulties 
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experienced with the human BRIC 216 antibody the results obtained were not always clear. 
Examples of two western blots displaying the technical difficulties experienced with the human DAF 
antibody can be found in Appendix D. As a result, for a few experiments only one result was 
obtained.  The data in Table 3.1 represents the average fold activation of two or three western 
blots based on densitometric readings, first normalized to tubulin expression and then to the 
respective untreated control cells and Figure 3.1 is a representative blot. As expected, LPS 
treatment increases (2.6-fold) WT DAF protein levels while repressing (3.3-fold) C>G DAF protein 
expression. In response to a range of prednisone doses (0.1, 1 and 3 µM doses), WT DAF protein 
expression did not fluctuate significantly although it did increase by 1.5-fold at a 60 µM dose, albeit 
not significant. Conversely, C>G DAF protein levels were repressed by 2.5-fold in response to 0.1, 1 
and 3 µM prednisone treatment while the 60 µM dose showed marginal repression (1.2-fold). 
Taken together, these data suggest prednisone doses of 3 µM and belo  greatly repress C>G DAF 
protein expression in lymphoblasts unlike that observed for WT DAF.  
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Table 3.1: The effect of prednisone on WT and C>G DAF mRNA and protein expression, and DAF promoter 
activity.  
 
 
 
 
 
 
 
 
(A) Total RNA was extracted from WT and C>G DAF lymphoblasts treated with 0.1, 1, 3 or 60 µM prednisone 
or LPS (10 µg/ml) for 24 and 19 hrs respectively. Relative fold expression was normalized to the house-
keeping gene GUS B. The results shown are of data pooled from three independent experiments each 
performed in duplicate and represent average fold activation compared to untreated control cells ± standard 
error of the mean (SEM). (B) The WT and C>G DAF luciferase reporter constructs were transiently 
transfected into COS-7 cells and treated with 0.1, 1, 3 or 60 µM prednisone or LPS (10 µg/ml) for 24 and 12 
hrs respectively thereafter promoter activity was determined. The result is representative of the average 
fold activation ±SEM of two (#) or three independent experiments in which each construct was tested in 
duplicate. (C) Total protein lysate was isolated from lymphoblasts 24 hrs post-treatment with 0.1, 1, 3 or 60 
µM prednisone or 19 hrs post-treatment with LPS (10 µg/ml)  and analysed on an 8% SDS-PAGE by western 
blotting using an antibody to DAF as well as an antibody to tubulin which was included as a loading control. 
The results are representative of the average densitometric readings of two (#) or three western blots. All 
densitometric reading results were first normalized to tubulin expression and then to the untreated control 
cells. (*) indicates significance at p≤0.05 between treated and untreated cells, (†) indicates significance 
between WT and C>G DAF at p≤0.05. 
 
 
 
 
 LPS Prednisone 
10 µg/ml 0.1 µM 1.0 µM 3 µM 60 µM 
A) Lymphoblast DAF mRNA levels 
WT 1.98 ± 0.07* 1.00 ± 0.04 1.33 ± 0.06 1.14 ± 0.13 1.70 ± 0.02 
C>G 0.69 ± 0.04* 1.07 ± 0.03 1.72 ± 0.06 0.88 ± 0.04 1.24 ± 0.06 
B) COS-7 DAF promoter activity  
WT  1.16 ± 0.01 0.90 ± 0.04 0.87 ± 0.02 1.30 ± 0.03* 1.35 ± 0.03* 
C>G 1.07 ± 0.11 0.80 ± 0.33 0.90 ± 0.22 1.02 ± 0.07# 1.06 ± 0.07# 
C) Lymphoblast DAF protein expression 
WT  2.6*†  1.2 0.8 1.2# 1.5  
C>G  0.3*† 0.4 0.4 0.4# 0.8 
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Figure 3.1: Prednisone is more repressive towards C>G DAF protein expression compared to WT DAF. Total 
protein lysate was isolated from lymphoblasts 24 hrs post-treatment with 0.1 and 1 µM of prednisone. Total 
protein from each sample was analysed on an 8% SDS-PAGE and assessed by western blotting using antibody 
to DAF as well as an antibody to tubulin which served as a loading control. Arrows indicate the position of 
the proteins of interest as determined by the protein marker banding pattern shown on the left in 
kilodaltons (kDa).  
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3.1.2 Cytotoxicity of LPS, sera and prednisone on WT and C>G DAF lymphoblasts 
 
Based on our hypothesis, we speculated that MG patients with the C>G SNP were more susceptible 
to complement-mediated lysis due to an inadequate DAF response which may be exacerbated in 
the presence of MG drugs (e.g. prednisone) and an immune stress. Therefore, to investigate the 
effect of the SNP on DAF’s ability to protect against complement-mediated lysis, calcein assays 
were performed in WT and C>G DAF lymphoblasts. The assay is based on the principle that the 
highly lipophilic non-fluorescent compound calcein-AM readily permeates live intact cell 
membranes. Once in the cell it is hydrolysed by esterases to form the strongly fluorescing molecule, 
calcein and hence fluorescence generated is used as a direct measure of cell viability.  
We assessed the lytic response of lymphoblasts expressing WT and C>G DAF in response to 
treatment with either LPS (10 µg/ml), 0.1 or 1 µM prednisone, MG treatment-naïve patient sera 
(hereafter referred to as MG sera) or control sera (derived from healthy individuals) alone or 
combinations of sera and prednisone treatment. It is important to note that the DAF genotypes of 
the sera used from the MG patients and control individuals is unknown. The MG sera was taken 
from newly diagnosed patients who had the presence of the ocular phenotype, while the control 
sera was derived from healthy individuals who did not have MG. The cytotoxicity effect of the 
respective sera on WT and C>G DAF lymphoblasts was investigated because MG auto-antibodies 
and activated complement are essential for disease pathogenesis. It is important to note that in 
control sera no pathogenic auto-antibodies or significant levels of activated complement are 
expected to be present. The assay was performed as described in section 2.10 and three controls 
were included; background control was subtracted from all measurements, a low lysis control was 
untreated normal cells and the high lysis control represented maximum calcein release after 40% 
triton X-100. The results are presented as specific calcein release as measure of % cytotoxicity= 
(test sample-low control)/(high control–low control) x100. The results shown in Figure 3.2 are 
representative of pooled data from two independent experiments each performed in triplicate. In 
response to 12 hrs of LPS treatment the C>G DAF lymphoblasts showed a trend to greater cell lysis 
(62%) compared to lymphoblasts with WT DAF (32%) (p<0.1), although this was not significant. This 
supports the hypothesis of this study that LPS results in lower DAF expression in the C>G SNP 
lymphoblasts thereby increasing the susceptibility of the lymphoblasts to complement-mediated 
lysis.  
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To determine the effect of control and MG sera on the lytic susceptibility of WT versus C>G DAF 
lymphoblasts, cells were treated with a range of dilutions (2.5, 5 and 10%) of either sera for 3 hrs. 
In response to the most diluted concentration of control sera (2.5%), WT DAF lymphoblasts 
exhibited a greater cytotoxic response (33%) compared to C>G DAF lymphoblasts (9%). This may be 
due to C>G DAF lymphoblasts expressing higher (up to 8-fold more) basal levels of DAF protein 
compared to WT (Heckmann et al., 2010) thereby providing the C>G DAF lymphoblasts with 
increased protection against “sublytic levels” of complement normally present in control sera (Lang 
et al., 1997). Various control sera at higher dilutions (5-10%) proved more cytotoxic compared to 
2.5% sera, but equally lytic to both WT and C>G DAF lymphoblasts (approximately 39%). In contrast, 
MG sera even at the lowest dilution of 2.5% displayed similar cytotoxicity of approximately 60% for 
both cell lines. The observation that 2.5% MG sera showed similar cytotoxicity to both WT and C>G 
DAF lymphoblasts is probably due to the presence of factor(s), such as activated complement, in 
the serum that increase the susceptibility of the cells to complement-mediated lysis. Ideally, an 
even lower dose (1%) should have been used to assess whether it had a differential cytotoxic effect. 
The cytotoxicity of prednisone treatment on WT versus C>G DAF lymphoblasts was next 
determined by treating the cells for 24 hrs with 0.1, 1 or 3 µM prednisone. A low dose (0.1 µM) of 
prednisone induced very little cell lysis in both the WT and C>G DAF lymphoblasts (approximately 
8.5%). However, 50% of the C>G DAF lymphoblasts lysed in response to the higher doses of 
prednisone compared to 16% WT DAF control lymphoblasts (pooled data for 1-3 µM shown is 
representative of 1 and 3 µM independently). Although this difference was not statistically 
significant, these results suggest that the C>G SNP increases the risk of cell lysis in response to 
higher doses of prednisone. 
Due to the increased cytotoxicity of MG sera on lymphoblasts, the combined effect of prednisone 
and MG sera was next investigated on the lytic response of WT versus C>G  DAF lymphoblasts. In 
response to 0.1 µM prednisone and 2.5% MG sera, almost 50% of the WT DAF lymphoblasts lysed 
and up to 70% of the C>G DAF lymphoblasts underwent cell lysis. Strikingly, the combination of MG 
sera and a higher dose of 3 µM prednisone resulted in cell lysis of 82% of C>G DAF lymphoblasts 
compared to only 9% of WT DAF lymphoblasts (p<0.05). Taken together, these data suggest that 
the combination of MG sera and prednisone reduces DAF protein expression in C>G DAF 
lymphoblasts thereby increasing their susceptibility to complement-mediated lysis. In contrast, the 
WT DAF lymphoblasts exposed to MG sera and prednisone, showed significantly less cell lysis. 
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Figure 3.2: Cytotoxicity of prednisone on C>G DAF lymphoblasts is significantly enhanced in the presence 
of MG sera compared to lymphoblasts expressing WT DAF. Calcein assays were performed on WT or C>G 
DAF lymphoblasts treated alone or in combination with LPS (10 μg/ml) for 12 hrs, control sera (CS) (2.5%-
10%) or MG sera (MGS) (2.5%-10%) for 3 hrs and prednisone (0.1, 1 or 3 µM) for 24 hrs. To obtain % 
cytotoxicity, fluorescence obtained after exposure of cells to Calcein-AM for 30 mins was normalized to the 
positive control, 40% Triton-X100 (20 mins treatment). The result shown is data pooled from two 
independent experiments performed in triplicate. Error bars represent standard error of the mean. (*) 
indicates a trend with p<0.1 and (**) indicates significance p<0.05. 
 
 
 
 
 
 
0
20
40
60
80
100
LP
S
C
S 
5
%
-1
0
%
C
S 
2
.5
%
M
G
S 
5
%
-1
0
%
M
G
S 
2
.5
%
0
.1
 µ
M
 P
re
d
1
-3
 µ
M
 P
re
d
M
G
S 
2
.5
%
 +
 0
.1
 µ
M
P
re
d
M
G
S 
2
.5
%
 +
 3
 µ
M
 P
re
d
%
 C
yt
o
to
xi
ci
ty
 
WT DAF
C>G DAF
* 
** 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
41 
 
3.1.3 Effect of prednisone and LPS on WT Daf in skeletal muscle cells  
As mentioned previously, a subset of MG patients develop a severe paralysis affecting the 
extraocular muscles, which is treatment-resistant. A more relevant approach would thus have been 
to study the effect of prednisone on muscle cells. However, extraocular muscle cell lines expressing 
either WT or C>G DAF were not available and therefore we opted to test the effect of current MG 
drugs on C2C12 skeletal myoblasts expressing WT Daf2. These myoblasts were differentiated over a 
period of 9 days into myotubes by changing the growth medium to differentiation medium 
supplemented with 2% horse serum (Figure 3.3). Importantly, while we did not have access to a 
C>G DAF muscle cell line this study was considered relevant because to date there is no published 
data showing the effect of either prednisone or LPS on WT DAF expression in skeletal muscle. Six 
day differentiated C2C12 myotubes were treated for up to 72 hrs with a range of prednisone doses 
(0.1, 1, 3, 10 and 30 µM). Thereafter, protein was harvested and analysed by western blotting using 
an antibody to mouse polyclonal Daf (sc-9156) or an antibody to tubulin which was used as a 
loading control. The data in Table 3.2 is representative of the average fold activation of two or 
three western blots based on densitometric readings first normalized to tubulin expression and 
then to the respective untreated cells. The results show that under all conditions tested WT Daf 
protein is repressed in response to prednisone in the differentiated C2C12 myotubes when 
compared to the untreated control cells. A representative blot is shown in Figure 3.4 and includes 
prednisone treatments of 0.1, 1, 3 and 10 µM.  
 
 
 
 
 
 
 
                                                          
2
 Nomenclature used to describe mouse decay-accelerating factor  
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Figure 3.3: Image of myoblasts differentiated into myotubes (40X). C2C12 myoblasts were differentiated 
for six days into myotubes by changing the growth medium (DMEM + 10% FCS + 1% P/S) to differentiation 
medium (DMEM   2  Horse Serum   1  P/S) and incubating them at 37 C. After six days the spindle-shaped 
myoblast-like cells started to fuse together and form the long thin muscle fibres (shown by the arrow). 
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Table 3.2: Effect of prednisone, LPS and control or MG sera treatment on WT Daf protein levels in C2C12 
muscle cells.   
 No 
Prednisone 
0.1 µM 
Prednisone 
1 µM 
Prednisone 
3 µM 
Prednisone 
10-30 µM 
Prednisone 
C2C12 cells 1.0 0.4 0.2 0.2 0.5# 
+ LPS  
(10 µg/ml) 
1.6 1.2 - 0.2 0.5# 
+ 10% Control 
Sera 
0.8 0.8 1.0 0.7*# - 
+ 10% MG sera 1.1 0.2 0.3 0.5*# - 
 
Six day differentiated C2C12 cells were treated with 0.1, 1, 3, 10 or 30 µM prednisone in the absence or 
presence of either LPS for 24 hours or 10% Control or 10% MG sera for 24 hrs. Thirty micrograms of total 
protein was separated on an 8% SDS-PAGE and analysed by western blotting using antibodies to Daf and 
tubulin. The results are representative of the mean of the densitometric readings of two (#) or three western 
blots. All densitometric reading results were first normalized for tubulin expression and then to the 
untreated control cells. (*) indicates significance at p≤0.05. 
 
The effect of prednisone on WT Daf protein levels under conditions of immune stress was next 
investigated. Here, 6 day differentiated C2C12 cells were treated with prednisone for a total of 72 
hrs in the presence or absence of LPS during the last 24 hrs of treatment, thereafter the protein 
was harvested and analysed by western blotting as described above. As shown in Table 3.2, LPS on 
its own increased WT Daf protein expression much like its effect in WT DAF lymphoblasts (Table 
3.1). When LPS was combined with 3, 10 and 30 µM doses of prednisone the repressive effect seen 
for prednisone treatment-alone was observed. Interestingly, WT Daf levels remained stable (1.2-
fold) after a low dose (0.1 µM) of prednisone treatment combined with LPS stimulation suggesting, 
at least in mouse muscle cells, lower doses of prednisone treatment maintain WT Daf at basal levels 
under conditions of immune stress. 
Overall, prednisone doses ranging from 0.1 to 30 µM had a repressive effect on WT Daf protein 
expression in mouse muscle cells. Under conditions of immune stress such as those mimicked by 
LPS, higher prednisone doses of 3 µM to 30 µM also resulted in severe WT Daf repression.  
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Figure 3.4: Prednisone downregulates WT Daf in mouse skeletal muscle cells. Six day differentiated C2C12 
myotubes were treated with 0.1, 1 or 10 µM prednisone for up to 72 hrs after which cell lysates (30 µg) were 
separated on an 8% SDS-PAGE and analysed by western blotting using antibodies to Daf and tubulin. The 
arrows indicate the position of the proteins of interest as determined by the protein marker banding pattern 
shown on the left in kilodaltons (kDa). 
 
3.1.4 MG treatment-naïve patient sera is unable to overcome the repressive effect of prednisone 
on WT Daf protein levels in muscle cells  
Since auto-antibodies and activated complement are essential in the pathogenesis of MG, we next 
looked at the effect that active treatment-naïve MG patient sera (MG Sera) had on WT Daf protein 
expression in differentiated C2C12 myoblast cells. Briefly, C2C12 cells were differentiated for 6 days 
to form myotubes and then treated with prednisone (0.1, 1 or 3 µM)  for a total of 72 hrs in the 
presence or absence of either 10% control sera (from healthy individuals) or 10% MG sera for 24 
hrs. C2C12 cells cultured under standard differentiation conditions i.e. with differentiation medium 
were included as a control. The results in Table 3.2 show the average fold change compared to 
untreated control cells from two or three western blots and a representative blot is shown in Figure 
3.5. WT Daf protein levels were reduced by 1.3-fold in response to control sera alone while in 
combination with 3 µM prednisone a significant repression of 1.4-fold (p≤0.05) was observed. 
However, lower doses of prednisone combined with control sera either did not show significant 
repression or remained basal. In contrast, MG sera treatment alone had no effect on WT Daf 
protein expression but interestingly in combination with all doses of prednisone tested WT Daf 
expression was greatly repressed (3 µM prednisone, p≤0.05).  
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Taken together, the above data suggests that the composition of control and MG sera are different 
and that factor(s) in the control sera has/have the ability to reduce the repressive effect of 
prednisone on WT Daf expression in mouse skeletal muscle cells.  
It is important to note that in these experiments the mouse polyclonal Daf antibody (sc-9156) gave 
clear and reproducible bands (Figure 3.5). Sometimes multiple banding patterns were achieved and 
in such cases all bands were analysed in the 70 to 100 kDa range, as specified in the data sheet 
accompanying the Daf antibody, and used as the signature for WT Daf protein expression in the 
C2C12 myoblasts. Unfortunately due to technical difficulties and inconsistent results experienced 
with the calcein assay in C2C12 cells, we were unable to assess the effect of prednisone and control 
or MG sera on the lytic response of these cells. 
 
 
 
 
 
 
 
 
 
Figure 3.5: Control sera, unlike MG sera, overcomes the repressive effect of prednisone on WT Daf protein 
in mouse skeletal muscle cells. Six day differentiated C2C12 myotubes were treated with 0.1 or 1 µM 
prednisone for a total of 72 hrs in the absence or presence of 10% control sera (CS) or 10% MG sera (MGS) 
for 24 hrs. Cells cultured under standard differentiation conditions where included as a control. Thirty 
micrograms of cell lysate was separated on an 8% SDS-PAGE and analysed by western blotting using 
antibodies to Daf and tubulin. The arrow and bracket indicate the position of the proteins of interest as 
determined by the protein marker banding pattern shown on the left in kilodaltons (kDa). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
46 
 
3.2 Effect of immunosuppressive steroid-sparing drugs alone or in combination 
with prednisone on DAF expression 
As previously mentioned, prednisone often results in side effects which become intolerable in the 
long-term. Immunosuppressive steroid-sparing drugs are thus commonly administered to patients 
to allow for a gradual decrease in this prednisone induced toxicity while still maintaining MG 
immunosuppressive treatment. The second aim of this study was therefore to determine the 
effect(s) of current MG immunosuppressive steroid-sparing drugs, cyclosporin A, azathioprine and 
methotrexate on WT and C>G DAF expression alone or in combination with prednisone.  
3.2.1 Cyclosporin A post-transcriptionally represses both WT and C>G DAF expression  
To determine the effect of cyclosporin A (CsA) on WT and C>G DAF mRNA levels, lymphoblasts were 
treated with 0.25 or 5 µM CsA for a total of 48 hrs with or without LPS (10 µg/ml) for 19 hrs.  Total 
RNA was isolated, reverse transcribed into cDNA and DAF mRNA levels quantified by qRT-PCR. The 
doses of CsA were selected based on similar concentrations used in published studies (Chen et al., 
2004; Düfer et al., 2001). Table 3.3 shows the average fold change, compared to untreated control 
cells, from three independent experiments each performed in duplicate. In response to 0.25 and 5 
µM CsA, WT DAF mRNA levels were slightly increased by approximately 1.3-fold, while C>G DAF 
mRNA levels showed no significant change and remained basal. While not statistically significant, 
the co-treatment of 0.25 µM CsA and LPS increased WT DAF mRNA expression (1.4-fold) but 
repressed C>G DAF mRNA levels (1.3-fold). The higher, 5 µM CsA dose in combination with LPS 
further repressed C>G DAF mRNA expression to 1.5-fold while WT DAF mRNA levels remained 
basal. Overall, the results suggest that the treatment of WT and C>G DAF lymphoblasts with either 
0.25 or 5 µM CsA, in the presence or absence of LPS, does not significantly influence DAF mRNA 
activity.  
To determine whether the effect of CsA on DAF mRNA levels is not transcriptional, luciferase 
reporter assays were performed. COS-7 cells transiently transfected with either the WT or C>G DAF 
promoter constructs were treated with 0.25 or 5 µM CsA for 24 hrs and extracts harvested 48 hrs 
post-transfection for firefly and renilla luciferase activity. The results of pooled data representing 
the average fold change from three independent experiments each performed in duplicate are 
shown in Table 3.4. The lower 0.25 µM CsA dose had no effect on WT or C>G promoter activity. 
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Although not significant, WT DAF promoter levels increased by 1.2-fold in response to 5 µM CsA 
treatment while C>G DAF promoter activity remained basal. The mRNA data above matched the 
trend seen at the promoter level as no significance was observed after CsA treatment. Therefore, 
CsA appears to have little regulatory effect on WT and C>G DAF mRNA levels and promoter activity. 
The effect of CsA on endogenous DAF protein levels was next investigated. Here, lymphoblasts 
expressing either WT or C>G DAF were treated with 0.25 or 5 µM CsA for 48 hrs in the absence or 
presence of LPS (10 µg/ml) for 19 hrs. Protein was extracted from the lymphoblasts and subjected 
to western blot analysis using antibodies to either DAF or tubulin (loading control). The data in 
Table 3.3 represents the average fold change of two independent western blots (unless specified) 
based on densitometric readings, first normalized to tubulin expression and then to the respective 
untreated control cells. Figure 3.6 (A) shows a representative western blot. The results suggest that 
WT DAF protein levels are repressed by 1.7-fold and 1.3-fold in response to both 0.25 and 5 µM CsA 
respectively, while C>G DAF protein levels are significantly repressed by 1.4-fold (p≤0.05) in 
response to either dose of CsA. In the presence of LPS, 0.25 µM CsA continues to repress both WT 
and C>G DAF protein expression by 1.4-fold and 2-fold respectively. Similarly, the co-treatment of 5 
µM CsA and LPS repressed WT DAF protein levels by 1.4-fold, whereas the same treatment 
combination increased C>G DAF protein expression 1.5-fold. However, only one western blot 
showing the effect of the co-treatment of CsA and LPS on WT and C>G DAF protein expression was 
obtained; therefore, this experiment will need to be repeated to confirm the above observations.  
Taken together, the data shows that in response to CsA the DAF mRNA and protein levels do not 
match suggesting that CsA has a post-transcriptional effect on DAF expression. Apart from the co-
treatment with 5 µM CsA and LPS which increased C>G DAF protein levels, WT and C>G DAF protein 
expression was consistently repressed in response to CSA, with or without LPS. This further 
suggests that, compared to WT DAF, the C>G SNP does not result in a differential regulatory effect 
on DAF expression in response to CsA treatment. 
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Table 3.3: The effect of MG drugs on lymphoblast (WT and C>G) DAF mRNA and protein expression. 
                             (A)  mRNA (B)   Protein 
Drug Dose (µM) Time (hrs) WT C>G WT C>G 
Cyclosporin A 0.25 48 1.32 ±  0.20 0.92 ± 0.01 0.6 0.7* 
 0.25 + LPS 48 1.43 ± 0.05 0.79 ± 0.09 0.7a 0.5a 
 5 48 1.25 ± 0.26 0.90 ± 0.04 0.8 0.7* 
 5 + LPS 48 1.04 ± 0.07 0.66 ± 0.02 0.7a 1.5a 
Azathioprine 5 24 1.60 ± 0.01* 1.02 ± 0.01 3.3† 0.4† 
 5 + LPS 24 1.40 ± 0.03* 0.92 ± 0.01 1.7 0.8 
Methotrexate 10 24 0.89 ± 0.09 0.87 ± 0.10 0.9 1.4 
 10 + LPS 24 1.37 ± 0.02 0.89 ± 0.04 2.4 1.0 
 22 24 0.94 ± 0.06 0.84 ± 0.04 0.9 1.8* 
 22 + LPS 24 0.90 ± 0.03 0.80 ± 0.10 1.6 1.2 
 
Total RNA or protein was extracted from WT and C>G DAF lymphoblasts treated with cyclosporin A, 
azathioprine or methotrexate for the specified hrs in the absence or presence of LPS (10 µg/ml) for 19 hrs. 
(A) WT and C>G DAF mRNA levels. All results were normalized to the house-keeping gene GUS B and the 
data shown is the average fold change, compared to the untreated control cells, of three independent 
experiments each performed in duplicate. Error bars represent standard err r of the mean. (B) WT and C>G 
DAF protein levels. Total protein lysate (40 µg) was analysed on an 8% SDS-PAGE by western blotting using 
an antibody to DAF as well as an antibody to tubulin which was included as a loading control. Unless 
indicated, the data shown is the average fold change obtained from densitometric readings from at least two 
independent western blot experiments. Fold change was calculated by first normalizing densitometric 
readings obtained for DAF levels to tubulin levels and then to their respective untreated control cells. (*) 
indicates significance at p≤0.05 between treated and untreated control cells, (†) indicates significance 
between WT and C>G DAF at p≤0.05, (a) indicates the results are representative of one experiment. 
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Table 3.4: The effect of steroid-sparing drugs on WT and C>G DAF promoter activity in COS-7 cells. 
DAF promoter activity 
 Dose WT C>G 
Cyclosporin A 0.25 µM 0.94 ± 0.03 0.90 ± 0.05 
 5 µM 1.24 ± 0.04 1.01 ± 0.05 
Azathioprine 5 µM 0.82 ± 0.02 0.87 ± 0.05 
Methotrexate 10 µM 1.99 ± 0.17* 2.16 ± 0.10* 
 22 µM 2.03 ± 0.15* 2.16 ± 0.06* 
 
The WT and C>G DAF luciferase reporter constructs were transiently transfected into COS-7 cells and treated 
24 hrs post-transfection with the indicated doses of either cyclosporin A, azathioprine or methotrexate 24 
hrs after which promoter activity was determined. The result shown is the average fold change, compared to 
untreated control cells, from three independent experiments each performed in duplicate. Error bars 
represent standard error of the mean. (*) indicates significance at p≤0.05 between treated and untreated 
control cells. 
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Figure 3.6: Effect of steroid-sparing agents on WT and C>G DAF protein expression. Total protein lysate was 
isolated from lymphoblasts 24 hrs post-treatment with either A) 0.25 and 5 µM cyclosporine A (CsA), B) 5 
µM azathiorprine (AZA) or C) 10 and 22 µM methotrexate (MTX). In B) LPS (10 µg/ml) was included in the last 
19 hrs of treatment prior to harvesting. Total protein from each sample was analysed on an 8% SDS-PAGE 
and assessed by western blotting using an antibody to DAF as well as an antibody to tubulin which served as 
a loading control. Arrows indicate the position of the proteins of interest as determined by the protein 
marker banding pattern shown on the left in kilodaltons (kDa). 
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3.2.2 Azathioprine differentially regulates WT and C>G DAF at both an mRNA and protein level  
To determine the effect of azathioprine (AZA) on WT versus C>G DAF mRNA expression, 
lymphoblasts were treated with 5 µM AZA for 24 hrs with or without LPS as described before. The 
dose of AZA selected for this study was based on similar concentrations used in a published study 
(Bobbala et al., 2009). Total RNA was isolated post-treatment, reverse transcribed into cDNA and 
analysed by qRT-PCR. The results in Table 3.3 show the average fold change, compared to 
untreated control cells, of three independent experiments each performed in duplicate. In the 
presence or absence of LPS, AZA significantly upregulated WT DAF mRNA levels by 1.6-fold 
(p=0.008) and 1.4-fold (p=0.002) respectively, while C>G DAF mRNA expression showed no change 
in response to treatments.  
As for CsA above, the effect of AZA on WT and C>G DAF promoter activity was next determined. 
Transfected COS-7 cells were treated with 5 µM AZA for 24 hrs and extracts assayed 48 hrs post-
transfection for firefly and renilla luciferase activity. Table 3.4 shows the average fold activation, 
compared to untreated control cells, from three independent experiments each performed in 
duplicate. Both WT and C>G DAF promoter activity showed no significant change compared to their 
respective untreated control cells in response to 5 µM AZA treatment. Overall, unlike results 
obtained for WT DAF, the C>G DAF promoter activity matched the trend seen for the mRNA results 
above. A possible explanation as to why AZA increased WT DAF mRNA levels while WT DAF 
promoter activity remained basal may reflect differences in the regulation of the endogenous gene 
compared to the in vitro promoter system in response to AZA. Furthermore, there may be 
differences in the cell-type specific responses to the drug.  
To determine the effect of AZA on endogenous DAF protein levels, WT and C>G DAF lymphoblasts 
were treated as described previously for qRT-PCR. Protein was extracted from lymphoblasts and 
subjected to western blot analysis using antibodies to either DAF or tubulin which was included as a 
loading control. The data shown in Table 3.3 represents the average fold change of two 
independent western blots based on densitometric readings, first normalized to tubulin expression 
and then to the respective untreated control cells. Wild-type DAF protein levels significantly 
(p=0.018) increased by 3.3-fold in response to AZA when compared to C>G DAF protein levels, that 
in turn were repressed by 2.5-fold. Although not significant, co-treatment with LPS and AZA 
increased WT DAF protein levels by 1.7-fold while it led to a 1.2-fold repression of C>G DAF protein 
levels. The lower WT DAF protein increase after AZA+LPS treatment is likely due to a complex cross-
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talk between AZA and LPS cell signalling. The western blot in Figure 3.6 (B) is representative of the 
results in Table 3.3 above. Taken together, these results suggest that AZA in the presence or 
absence of LPS upregulates WT DAF protein expression while LPS alleviates the repressive effect 
seen for AZA-only treatment on C>G DAF protein levels.  
Overall, AZA appears to have a post-transcriptional repressive effect on C>G DAF but a 
transcriptional activation effect on WT DAF. 
3.2.3 Methotrexate does not repress WT or C>G DAF expression  
To investigate the effect of methotrexate (MTX) on WT versus C>G DAF mRNA expression, 
lymphoblasts were treated with a low (10 µM) and a high (22 µM) dose of MTX for 24 hrs with or 
without LPS as described before. Total RNA was isolated, reverse transcribed into cDNA and DAF 
mRNA levels quantified by qRT-PCR. The doses of MTX were selected because they were considered 
clinically relevant (Fotoohi et al., 2004). Table 3.3 shows the average fold change, compared to 
untreated control cells, from three independent experiments each performed in duplicate. In 
response to both 10 and 22 µM MTX no significant change was observed on either WT or C>G DAF 
mRNA levels. Although not significant, WT DAF mRNA levels increased by 1.4-fold in response to 10 
µM MTX in the presence of LPS unlike C>G DAF mRNA levels which remained basal. Furthermore 22 
µM MTX with LPS treatment had no significant effect on either WT or C>G DAF mRNA expression. 
These results therefore suggest that MTX has little regulatory effect on WT and C>G DAF mRNA in 
lymphoblasts. 
We next investigated the effect of MTX on WT and C>G DAF promoter activity. Here, COS-7 cells 
transiently transfected for 24 hrs were treated with 10 or 22 µM MTX for 24 hrs and extracts 
assayed for firefly and renilla luciferase activity. The results of the average fold change, compared 
to untreated control cells, from three independent experiments each performed in duplicate are 
shown in Table 3.4. In response to both doses of MTX, WT and C>G DAF promoter activity 
significantly (p≤0.05) increased by approximately 2-fold compared to untreated control cells. These 
data do not reflect those generated at an mRNA level above and may reflect differences in the 
regulation of endogenous gene expression and in vitro promoters.  
To determine the effect of MTX on endogenous DAF protein levels, WT and C>G DAF lymphoblasts 
were treated as described for qRT-PCR above. Protein was extracted from lymphoblasts and 
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subjected to western blot analysis using antibodies to either DAF or tubulin which was included as a 
loading control. The data in Table 3.3 represents the average fold change of two independent 
western blots based on densitometric readings, first normalized to tubulin expression and then to 
the respective untreated control cells. A representative western blot is shown in Figure 3.6 (C). 
Whereas WT DAF protein levels were unchanged in response to both concentrations of MTX 
treatment, C>G DAF protein levels showed a 1.4-fold and 1.8-fold (p=0.004) increase in response to 
the 10 and 22 µM MTX doses respectively. The co-treatment of both MTX doses with LPS increased 
WT DAF protein expression by 2.4-fold and 1.6-fold but only the higher 22 µM dose of MTX in 
combination with LPS increased C>G DAF protein levels by 1.2-fold. Overall, MTX in the presence or 
absence of LPS did not inhibit WT or C>G DAF protein expression. These results have important 
implications for MG patients harbouring the C>G SNP because they suggest that MTX treatment 
does not repress DAF expression.  
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3.2.4 Effect of steroid-sparing drugs on WT Daf in skeletal muscle cells  
As for prednisone, we next assessed the effect of the steroid-sparing drugs CsA, AZA and MTX on 
WT Daf expression in skeletal muscle cells. Here, six day differentiated C2C12 myoblasts were 
treated with the indicated doses of each drug alone for a total of 72 hrs with or without LPS (10 
µg/ml) for 24 hrs. Thereafter, protein was harvested and analysed by western blotting using an 
antibody to mouse polyclonal Daf or an antibody to tubulin which was included as a loading control. 
The results shown in Table 3.5 represents the average fold change of two independent western 
blots based on densitometric readings, first normalized to tubulin expression and then to the 
respective untreated control cells. Figure 3.7 shows representative western blots of data depicted 
in Table 3.5. In response to 0.25 and 5 µM CsA, WT Daf protein levels increased by 2.2-fold and 1.7-
fold respectively and this activation response was maintained in the presence of LPS (1.4-fold and 
1.6-fold respectively). AZA (5 µM) treatment increased WT Daf protein expression by 2.1-fold while 
the co-treatment of AZA and LPS increased WT Daf levels by 1.5-fold (p≤0.05). In the presence of 10 
µM and 22 µM MTX, WT Daf protein levels increased by 2-fold and 1.8-fold respectively while co-
treatment of MTX with LPS reduced the observed activation response to basal (10 µM MTX+LPS) or 
below basal (22 µM MTX+LPS) levels.  
Overall, the results for AZA and MTX, but not CsA, match the trend seen in WT DAF lymphoblasts 
i.e. treatment with these steroid-sparing agents alone do not appear to repress WT Daf protein 
levels in the differentiated C2C12 myotubes. This was also true for the co-treatment of LPS with 
CsA, AZA or a lower dose of MTX.  
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Table 3.5: The effect of MG drugs on WT Daf protein expression in differentiated C2C12 mouse myotubes. 
C2C12 Daf protein expression 
 - + LPS  
(10 µg/ml) 
Prednisone 
0.1 µM  1 µM  
Cyclosporin A 0.25 µM 2.2 1.4 1.0 0.9 
 5.0 µM 1.7 1.6 0.3 0.2 
Azathioprine 5.0 µM 2.1 1.5* 0.9 1.0 
Methotrexate 10 µM 2.0 0.9 0.8 0.9 
 22 µM 1.8 0.7 0.7 0.6 
 
Total protein was isolated from six day differentiated C2C12 myotubes treated with cyclosporine A, 
azathioprine or methotrexate for 24 hrs in the absence or presence of LPS for 24 hrs.  Cell lysates (30 µg) 
were separated on an 8% SDS-PAGE and analysed by western blotting using antibodies to Daf and tubulin. 
The results represent the average fold change of two independent western blots based on densitometric 
readings, first normalized to tubulin expression and then to the respective untreated control cells. (*) 
indicates significance at p≤0.05 between treated and untreated control cells. 
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Figure 3.7: Steroid-sparing immunosuppressive drugs used in the treatment of MG do not repress WT Daf 
protein levels in mouse skeletal muscle cells. Six day differentiated C2C12 myotubes were treated with 
either (A) 0.25 and 5µM cyclosporine A (CsA) or (B) 5 µM azathioprine (AZA) or (C) 10 and 22 µM 
methotrexate (MTX) all for a total of 72 hrs with or without LPS (10 µg/ml) for 24 hrs. In (A), (B) and (C) cell 
lysates (30 µg) were separated on an 8% SDS-PAGE and analysed by western blotting using antibodies to Daf 
and tubulin. The bar graph represents the densitometric readings comparing the intensity of the DAF protein 
normalized to the tubulin loading control. The arrows and brackets indicate the position of the proteins of 
interest as determined by the protein marker banding pattern shown on the left in kilodaltons (kDa). 
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3.2.5 Effect of prednisone in combination with steroid-sparing drugs on WT Daf in a skeletal 
muscle model   
To further investigate the effect of prednisone in combination with the steroid-sparing drugs on WT 
DAF expression, mouse skeletal myoblasts differentiated for 6 days into myotubes were treated 
with either 0.1 or 1 µM prednisone for a total of 72 hrs. Protein was harvested and analysed by 
western blotting as described above in section 3.2.4. The data in Table 3.5 shows the average fold 
change of two independent western blots based on densitometric readings, first normalized to 
tubulin expression and then to the respective untreated control cells. The 0.25 µM dose of CsA in 
combination with both doses of prednisone maintained WT Daf protein levels at a basal level; 
however, although not statistically significant, 5 µM CsA combined with 0.1 or 1 µM prednisone 
greatly repressed WT Daf (3.3-fold and 5-fold respectively). Interestingly, 5 µM AZA was able to 
overcome the repressive effect seen for 0.1 and 1 µM prednisone in Table 3.2 and also shown in 
Figure 3.8. This was also seen for 10 µM MTX while a repressive effect was observed for the co-
treatment of 22 µM MTX with 0.1 or 1 µM prednisone (1.4-fold and 1.7-fold respectively). Taken 
together, these results suggest that AZA and the lower doses of CsA and MTX in combination with 
prednisone prevent the repression of WT Daf protein levels by prednisone in the skeletal C2C12 
muscle cells.   
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Figure 3.8: Azathioprine in combination with prednisone maintains basal WT Daf protein levels in C2C12 
mouse myotubes. Six day differentiated C2C12 myotubes were treated with 5 µM azathioprine (AZA) with or 
without 0.1 and 1 µM prednisone for 72 hrs. Cell lysates (30 µg) were separated on an 8% SDS-PAGE and 
analysed by western blotting using antibodies to Daf and tubulin. The bar graph represents the 
densitometric readings comparing the intensity of the DAF protein normalized to the tubulin loading control. 
The arrows indicate the position of the proteins of interest as determined by the protein marker banding 
pattern shown on the left in kilodaltons (kDa). 
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Chapter 4: Discussion 
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease in which autoantibodies 
target the acetylcholine receptors (AChRs) of the neuromuscular junction. Recently our laboratory 
identified a functional c.-198C>G SNP (C>G SNP) in the promoter of decay accelerating factor (DAF). 
This SNP was shown to be significantly associated with the development of a severe treatment-
resistant extraocular phenotype in MG patients. As MG patients with this C>G SNP developed 
ophthalmoplegia while on standard treatment this thesis focused on the effects of drugs used in 
the management of MG on wild-type (WT) and C>G DAF expression levels. The data obtained 
increases our understanding of DAF expression in response to these drugs at the molecular level 
and have implications for the treatment of MG patients carrying the C>G SNP.  
4.1 The effect(s) of prednisone on wild-type versus C>G DAF expression 
Repression of C>G DAF protein levels by prednisone increases the risk of cell lysis 
This is the first study to investigate the effect of prednisone, the first-line immunosuppressive drug 
used in MG, on DAF expression in human lymphoblasts. Lymphoblast cell lines were first 
established from healthy control individuals expressing WT DAF or from MG patients harbouring 
the C>G DAF SNP. Subsequently, DAF mRNA and protein levels were determined after the exposure 
of these lymphoblast cell lines to different doses of prednisone. Overall, prednisone doses between 
0.1 and 60 µM did not appear to have a regulatory effect on WT or C>G DAF mRNA expression or 
promoter activity as levels remained close to basal or no statistical significance was achieved. 
However, western blotting performed on total protein revealed that a range of prednisone doses 
has a repressive effect on C>G DAF but not WT DAF protein levels. Indeed, in response to the 0.1, 1 
and 3 µM doses of prednisone, C>G DAF protein levels were repressed by 2.5-fold compared to WT 
DAF.  
To determine the functional significance of C>G DAF protein repression by prednisone, calcein 
assays were performed. Although not significant, prednisone doses of 1-3 µM, but not 0.1 µM, 
were shown to increase the degree of cell lysis in C>G DAF lymphoblasts (50%) when compared to 
WT DAF (16%). Therefore, the results generated from the calcein assay indicate that WT DAF 
protein levels after exposure to prednisone treatment are sufficient to protect against cell lysis. 
Conversely, the repressive effect of the higher 1 and 3 µM prednisone doses on C>G DAF protein 
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levels appears to lead to an inadequate DAF response, that consequently results in cell lysis. 
Although western blot analysis indicated 0.1 µM prednisone was equally repressive towards C>G 
DAF (as seen for 1 and 3 µM prednisone), calcein assays suggested that C>G DAF lymphoblast have 
a low risk of undergoing cell lysis after exposure to this dose of prednisone. These results would 
suggest that the repression of C>G DAF at 0.1 µM prednisone is not sufficient to lead to cell lysis. It 
is however important to note that DAF is not the only complement regulatory protein expressed on 
lymphoblasts and it is possible that at higher doses of prednisone one or more of these are 
inactivated which together with decreased levels of C>G DAF results in cell lysis. Furthermore, this 
study also shows that while LPS, which mimics immune stress and which has previously been shown 
to repress C>G DAF protein levels (Heckmann et al., 2010), induced approximately 60% of the C>G 
DAF lymphoblasts to lyse it was only able to cause 33% of WT DAF lymphoblasts to undergo cell 
lysis (Figure 3.1). Together these results confirm that LPS or prednisone treatment reduced levels of 
C>G DAF expression which correlated directly with susceptibility to cell lysis. In addition they 
suggest that in our MG patients with the C>G SNP, prednisone treatment may be lowering their 
EOM DAF levels to below the threshold needed for optimal protection against complement-
mediated lysis. These observations may impact on treatment approaches for our MG patients 
harbouring the C>G SNP, as currently MG treatment protocols frequently use prednisone.  
Interestingly, when WT and C>G DAF lymphoblasts were treated with high concentrations (5%-10%) 
of either MG patient or control sera, there was a trend to greater cell lysis for the MG sera and the 
effect was comparable in WT and C>G DAF lymphoblasts. This was also the case for 2.5% MG sera 
which suggests that compared to control sera, MG sera is more cytotoxic irrespective of the 
presence or absence of the C>G SNP. For future experiments, the concentration of the active MG 
sera, which is expected to downregulate DAF much like LPS, should be further reduced for example 
to 1%, to establish whether there is a difference in cytotoxicity between WT and C>G DAF 
lymphoblasts. However, if after the above treatment the level of cytotoxicity remains similar, this 
could imply that the additional complement receptor proteins, but not DAF, are protecting against 
complement-mediated lysis. Results shown in Figure 3.1 also reveal that co-treatment with 3 µM 
prednisone and MG sera resulted in the death of 82% of C>G DAF lymphoblasts compared to 9% 
WT DAF lymphoblasts. This data suggests, that under conditions similar to the MG environment, 
albeit in vitro, the C>G SNP appears to significantly increase the risk of cell lysis after prednisone 
treatment.  
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Evidence in the literature suggests that, in response to prednisone treatment, the putative NFκB 
binding site introduced by the C>G SNP could play a significant role in the repression of C>G DAF 
protein levels. As mentioned previously, NFκB is critical for immune homeostasis and 
glucocorticoids, such as prednisone, are known to repress NFκB-driven pro-inflammatory genes. 
The mechanism by which glucocorticoids repress NFκB-driven genes is thought to be by direct 
protein-protein interaction of glucocorticoid receptors (GRs) with NFκB. For example, an in vitro 
study by Ray et al. (1994) showed that GRs associated with the NFκB subunit p65 which is required 
for binding essential components of the basal transcriptional machinery such as TFIIB and TBP 
(Schmitz et al., 1995). The binding of GRs to p65 thus prevents its interaction with the basal 
transcriptional machinery and hence NFκB target genes are repressed. Additionally, GR binding to 
p65 may affect the interaction of p65 with other transcription factors and therefore influence the 
complex cross-talk that occurs amongst transcription factors involved in the immune regulatory 
pathways. It would be important for future studies to explore whether this is the mechanism by 
which prednisone represses C>G DAF an anti-inflammatory pathway.   
Prednisone represses WT Daf in a muscle model  
The effect of prednisone on DAF expression in muscle was of great interest because it is the 
extraocular muscles (EOM) that are affected in the MG phenotype under investigation. 
Unfortunately, at the time that this study was initiated neither an EOM cell line nor patient-derived 
muscle cell lines expressing WT or C>G DAF were available. Furthermore, there were no reports 
documenting the effect of prednisone on muscle DAF expression. Therefore, to gain an insight into 
the effect of prednisone on DAF expression in muscle, the experiments performed in lymphoblasts 
were repeated in a C2C12 mouse myoblast cell line which expresses WT Daf. Overall, the data 
consistently showed that prednisone repressed WT Daf at various doses ranging from 0.1 to 30 µM 
in the differentiated mouse myotubes (Table 3.2). Furthermore, in the presence of LPS, prednisone 
doses of 3-30 µM continued to repress WT Daf protein levels. Interestingly, this data did not 
correspond with the results obtained in human lymphoblasts expressing WT DAF. While this 
suggests that the effects of prednisone may be species and/or cell-type specific the possibility 
cannot be excluded that prednisone may also repress DAF levels in human EOM. Interestingly, 
western blot analysis performed in the differentiated mouse myotubes showed that co-treatment 
of MG sera with prednisone, greatly repressed WT Daf protein expression, while control sera was 
able to overcome the repressive effect of prednisone (Table 3.2). This suggests that under 
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conditions mimicking MG in vitro, prednisone treatment represses WT Daf protein expression. 
Since corticosteroids, such as prednisone, can inhibit both the JNK pathway and affect the p65 NFκB 
pathway (De Bosscher et al., 2000), the combination of prednisone and a critical level of 
complement factors may thus contribute to a breach of muscle defences in cells susceptible to 
complement-mediated damage, such as EOMs in MG patients harbouring the C>G SNP. 
As mentioned previously in section 1.8.1, post-transcriptional modification is one mechanism by 
which glucocorticoids are thought to influence gene expression. The prednisone-induced 
lymphoblast DAF repression (and probably Daf myotube repression) observed in this thesis is highly 
suggestive of a post-transcriptional mechanism in these cell types as C>G DAF promoter activity and 
mRNA levels remained basal in response to prednisone. Therefore, to establish whether Daf protein 
repression by prednisone is transcriptional or translational in the C2C12 myotubes future 
experiments should include qRT-PCR analysis where Daf mRNA levels are quantitated.  
Based on the results of this study, the following model is proposed to explain the effects 
prednisone may have on DAF protein levels in MG patients expressing either WT or C>G DAF. Those 
MG patients with the C>G SNP who are administered prednisone and are exposed to an immune 
stress,may  have critically repressed DAF protein expression in their EOMs that is below the 
threshold necessary to protect against complement-mediated damage (Figure 4.1). As mentioned 
earlier, it is speculated that DAF expression is already low in the EOMs and is the dominant CRP 
required for complement-mediated lysis protection (Kaminski et al., 2004); therefore MG patients 
harbouring the C>G SNP would be more susceptible to EOM damage and hence development of the 
extreme EOM phenotype. Conversely, WT DAF protein expression is less repressed and levels are 
still sufficient to prevent autologous complement-mediated lysis in their EOMs. The validity of this 
model should be tested by examining both WT and C>G DAF protein expression levels in a human 
EOM cell line in response to prednisone treatment. 
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Figure 4.1: Schematic diagram of the proposed model showing the influences of prednisone treatment 
under conditions of immune stress on WT or C>G DAF protein expression in extraocular muscles.  
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4.2 The regulation of DAF/Daf expression in response to cyclosporin A, azathioprine 
and methotrexate  
The second aim of this study was to determine the effects of current MG immunosuppressive 
steroid sparing drugs, cycosporin A (CsA), azathioprine (AZA) and methotrexate (MTX), on WT and 
C>G DAF expression alone or in combination with prednisone. Overall, the studies in lymphoblasts 
as well as luciferase promoter reporter assays show that CsA has no statistically significant effect on 
the transcription of both WT and C>G DAF (Tables 3.3 and 3.4). CsA, however, under most 
conditions tested repressed WT and C>G DAF protein levels in lymphoblasts even in the presence of 
LPS which suggests that its regulation of DAF levels is post-transcriptional. It should however be 
pointed out that only one western blot was achieved for DAF protein analysis investing the co-
treatment of CsA with LPS, so these results should be interpreted with caution. Interestingly, the 
opposite results were obtained in the C2C12 muscle cells where CsA treatment alone or in 
combination with LPS was shown to increase WT Daf protein expression (Table 3.5). The 
discrepancy between results obtained in WT DAF lymphoblasts and mouse skeletal muscle C2C12 
cells suggests that CsA may exert cell-type and/or species-specific effects. Indeed, a cell type 
specific effect may explain the conflicting reports for the effect of CsA on DAF in the literature.  For 
example, whereas Mason et al (2004) showed that CsA has no effect on basal levels of DAF in 
human endothelial cells, CsA was reported to increase both DAF and CD49 expression in a kidney 
endothelial cell model (Kim et al., 2007). To date, the present study is the first to investigate 
combinations of drugs relevant to the clinical MG scenario. Importantly the co-treatment of skeletal 
muscle cells with a low 0.25 µM CsA dose together with prednisone showed that CsA was able to 
overcome the repressive effect as seen for prednisone-only treated cells. This therefore suggests 
these co-treatments, albeit in vitro, may be beneficial in a patient with complement-mediated 
extraocular muscle disease.  
To date, no reports exist on the effect(s) of AZA treatment on DAF expression and the results in this 
study show that WT DAF and C>G DAF are differentially regulated at both an mRNA and protein 
level. Whereas AZA increased WT DAF mRNA and protein levels, it did not affect C>G DAF mRNA 
levels but significantly repressed its protein levels (Table 3.3). Studies in the C2C12 mouse muscle 
model showed that, similar to results generated in WT DAF lymphoblasts, AZA upregulated WT Daf 
protein expression in the absence or presence of LPS. Importantly, the combination of AZA and 
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prednisone treatment of muscle cells overcame the repressive effect seen for prednisone-alone 
treatment on WT Daf. This has relevance to MG patients, as co-treatment of AZA and prednisone 
may therefore have a positive effect on EOM DAF levels although, to date, we do not know its 
effect in C>G DAF muscle. 
This thesis is the first to give an insight to the effect that MTX has on DAF expression. Of particular 
importance to the current thesis are the results from western blot analysis which showed that MTX 
treatment alone increased C>G DAF protein levels and that co-treatment of MTX with LPS had no 
effect on C>G DAF protein levels (Table 3.3). Interestingly, promoter studies indicated that MTX 
transcriptionally activates both WT and C>G DAF promoter activity (Table 3.4), while having no 
significant effect on WT and C>G DAF mRNA levels. Together these data suggest that the 
mechanism(s) by which MTX regulates DAF may be complex and an explanation for how MTX 
regulates C>G DAF protein levels is currently unknown. However the results are promising as MTX 
was the only drug studied in this thesis that did not repress C>G DAF protein expression which 
suggests that it may be an effective treatment for MG patients harbouring the C>G SNP. Indeed, a 
recent report has shown that MTX is a cost-effective alternative to AZA due to a similar efficacy and 
safety profile (Heckmann et al., 2011).  
4.3 Future considerations and limitations of this study 
As previously mentioned, the complement regulatory proteins (CRPs) including DAF, MCP, CD59 
and CR1 are expressed on the surface of most cells and serve critical roles in the body by preventing 
complement-mediated lysis in autologous cells. Indeed, DAF and CD59 are two complement 
regulatory proteins shown to be particularly important in the defence against EAMG-associated 
complement-mediated muscle damage (Kaminski et al., 2006; Morgan et al., 2006). Furthermore, 
experimental autoimmune MG studies found that DAF or CD59 knock-out mice showed activation 
of complement, AChR loss at the muscle endplate as well as detectable weakness compared with 
wild-type littermates (Kaminski et al., 2006; Morgan et al., 2006). Interestingly, Mason et al (2002) 
and Kusama et al (2003) demonstrated that DAF is the main CRP required for protection against 
complement-mediated lysis in human umbilical endothelium cells and swine endothelial cells 
respectively. Similarly, Kaminski et al (2004) found that in an experimental mouse autoimmune MG 
model that DAF expression in EOM was less than in other skeletal muscle but was more important 
then CD59 for the protection of EOM against complement-mediated damage. Conversely, in human 
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skeletal myoblasts CD59 was shown to be the main CRP, as its silencing, but not DAF’s, led to cell 
lysis (Gasque et al., 1996). It is therefore necessary to investigate the effects of the drugs studied in 
this thesis in an EOM cell line derived from control WT DAF individuals and C>G DAF expressing MG 
patients. These cell lines would be as close to the MG environment as possible, and the results 
would be more relevant than patient-derived lymphoblasts.  
Another drug which could be assessed in the efficacy of treatment for C>G SNP DAF MG patients is 
Eculizumab, a compliment inhibitor drug. It would be interesting to assess the response of MG 
patients with the extreme ocular phenotype to this drug alone or in combination with 
methotrexate. 
Furthermore, an obvious additional limitation of the current study is the use of cell culture models 
as they are in vitro and therefore the results obtained cannot reliably inform the treatment 
regimens in MG patients. In particular, the in vitro environment including the doses of drugs and 
treatment duration might not represent the in vivo situation and thus the results from the current 
study should be interpreted with caution.  
4.4 Conclusion 
This project focused on investigating current immunosuppressive drug therapies on DAF expression 
as well as to elucidate if any regulatory differences were present between WT and C>G DAF 
expression. The experimental findings in this thesis suggested that prednisone at specific doses, is 
repressive to lymphoblast C>G DAF protein expression more so than to WT DAF, and that the 
repression appears to significantly increase susceptibility to complement-mediated injury. 
Furthermore, prednisone showed a substantial repressive effect on the expression of myotube WT 
Daf. This may be of importance to MG patients who are susceptible to complement-mediated 
extraocular muscle damage. The postulate would be that EOMs with increased susceptibility to 
complement-mediated damage, such as a MG patient expressing C>G DAF, have an inadequate DAF 
response to prednisone treatment and an immune stress, which renders EOMs vulnerable.  
The steroid-sparing agents tested in this thesis showed that only MTX was able to increase or 
maintain basal expression of C>G DAF protein levels, suggesting that MTX may be an appropriate 
treatment for MG patients harbouring the C>G SNP. This thesis is the first to study the co-treatment 
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of prednisone with CsA, AZA or MTX on DAF expression and results would suggest that AZA and low 
doses of CsA and MTX are able to overcome the prednisone-induced Daf repression. 
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Appendix A: General recipes and reagents
 
Tissue culture 
Dulbucco’s Modified Eagles Medium 
13.55g DMEM 
3.7g sodium hydrogen carbonate 
Make to 1 litre with autoclaved ddH2O 
pH to 7.2 
Filter through 0.22 μM filter. 
Store at 4°C. Medium older than 3 weeks was 
re-supplemented with L-glutamine because of 
its instability. 
 
Penicillin/Streptomycin (P/S) 
900mg penicillin 
1500mg streptomycin 
Make up to 150 mls in sterile 1x PBS 
Filter through 0.22μM filter 
Store at -20°C. 
 
Trypsin-EDTA 
8g NaCl 
1.26g Na2HPO4 
0.2g KCl 
0.2g KH2PO4 
0.5g Trypsin 
0.2g EDTA 
Make up to 1 litre with dH2O 
pH to 7.4 
Filter sterilize through 0.22 μM filter 
Store at 4°C. 
 
Hoechst Stain Working Solution 
1ml Hoechst 33258 
100 mls Hanks balanced salt solution 
Wrap in tin foil and store at 4°C. 
 
Mounting Fluid 
22.2 mls 0.1M Citric acid 
27.8 mls 0.2M Na2HPO4.2H2O 
50 mls Glycerol 
Make up to 100 mls, pH to 5.5 
Store at 4°C. 
 
Gel electrophoresis 
 
2% Agarose Gel 
1g agarose powder 
50 mls 1xTBE (see below) 
 
 
 
Heat solution to dissolve agarose 
Cool to approximately 50°C 
Pour and allow to solidify. 
 
10x Tris-Borate-EDTA (TBE) Electrophoresis 
Buffer 
108g Tris 
55g Boric acid 
40 mls 0.5M EDTA (pH 8.0) 
Make up to 1 litre with dH2O 
Store at room temperature 
For use, dilute to 1x. 
 
Amplification of plasmids 
 
Luria Broth (LB) 
10g Bacto-tryptone 
5g Yeast extract 
10g NaCl 
Make up to 1 litre with ddH20 
pH to 7.0 
Autoclave and store at room temperature. 
 
LB agar 
15g agar to 1 litre of LB 
Autoclave and store at room temperature. 
 
Luciferase assays 
 
Serum-free medium 
49.25 mls DMEM 
250 µl FBS 
250 µl P/S 
Store at 4°C. 
 
RNA extraction 
 
DEPC Treatment 
0.1% DEPC in distilled water  
Stir for 30 mins 
Soak pipette tips and micro-centrifuge tubes 
in DEPC-treated water overnight. 
Remove as much of the DEPC-treated water 
then autoclave. 
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Western blotting 
RIPA buffer with SDS 
150 mM NaCl  
1% Triton X-100  
0.1% SDS  
20 mM Tris pH 7.5  
1% deoxycholate  
Make up to 50 mls with dH2O 
Store at 4°C. 
 
Supplement with 1 mg/ml aprotinin, 1 mg/ml 
pepstatin A, 2 mM phenylmethanesulfonyl 
fluoride protease inhibitors (Sigma, USA) and 
25x Proteinase Inhibitor Cocktail (Roche, 
Germany) just before use. 
 
RIPA Buffer without SDS 
150 mM NaCl  
1% Triton X-100  
50 mM Tris pH 8.0  
Make up to 10 mls with ddH2O. 
Filter sterilize with 0.45µm filter. Store at 4°C. 
Store at 4°C. 
 
Supplement with 1 mg/ml aprotinin, 1 mg/ml 
pepstatin A, 2 mM phenylmethanesulfonyl 
fluoride protease inhibitors (Sigma, USA) and 
25x Proteinase Inhibitor Cocktail (Roche, 
Germany) just before use. 
 
10x Phosphate Buffered Saline (PBS) 
160g NaCl 
4g KCl 
25.2g anhydrous Na2HPO4.12H2O 
4.8g KH2PO4 
Make up to 2 litres with dH2O 
pH to 7.4 then autoclave. 
Store at room temperature. 
 
1x PBS/0.1% Tween 
1x PBS made up to 1 litre 
1 ml Tween 20 
Mix well with stirrer bar 
Store at 4°C 
 
5% Skim-milk Blocking Buffer 
5% powder skim milk (w/v) 
Make up to 50 mls with 1x PBS/0.1% Tween 
Store at 4°C. 
 
Membrane Stripping Buffer 
100 nM β-Mercaptoethanol 
2% SDS 
62.5 mM Tris-Cl pH 6.7 
Fill up to final volume with dH2O. 
Cover in foil and store at room temperature. 
 
Calcein Assay 
 
1x Calcein Buffer 
Dilute 10x Calcein AM DW Buffer to 1x with 
ddH2O. 
 
2 µM Calcein-AM 
Suspend 50 µg Calcein-AM in 25 μl of 
anhydrous DMSO to make a 2 mM 
Calcein AM Stock Solution.  
For 2 µM Calcein-AM  working solution dilute 
in 1x calcein buffer (above). 
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Appendix B: Drug preparations 
 
1. Prednisone (Sigma P6254-1g) 
For 60 µM stock and treatment: 
Dissolve 0.022g prednisone in 1 ml pure ethanol:chloroform (1:1 ratio). Cover stock and 
working solutions with foil and store at -20°C. 
 
2. Cyclosporin A (Sigma C1832-5mg) 
For 10 μM stock: 
Dissolve 5 mg cyclosporin A in 0.416 μl pure ethanol. Cover stock and working solutions 
with foil and store at -20°C. 
 
3. Methotrexate (Sigma M8407-100mg) 
For 22 μM stock and treatment: 
Dissolve 9.9968 mg methotrexate in 1 ml 0.25M Na2CO3. Cover stock and working 
solutions with foil and store at -20°C. 
 
4. Azathioprine (Sigma A4638-1g) 
For 10 μM stock: 
Dissolve 2.77 mg of azathioprine in 1 ml NH4OH. Cover stock and working solutions with 
foil and store at -20°C. 
 
5. Lipopolysaccharide (Sigma L4391-1mg) 
For 10 μg/ml working solution: 
Dissolve 1 mg in 2 mls autoclaved 1 x PBS. Cover with foil and store at -20°C. 
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Appendix C: Molecular weight markers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GelPilot 100bp Plus (QIAGEN, USA) 
peqGold Prestained Protein Marker IV 
(PeqLab Biotechnologie, Germany) 
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Appendix D: Supplementary data 
 
Figure 5.1: Two examples showing the technical difficulties experienced with the 
human DAF monoclonal BRIC 216 antibody (IBGRL, UK). Total protein lysate was 
isolated from lymphoblasts 24 hrs post-treatment with 0.1 and 1 µM prednisone. 
Protein from each sample was analysed on an 8% SDS-PAGE and analysed by 
western blotting using an antibody to DAF. Arrows indicate the position of DAF as 
determined by the protein marker banding pattern shown on the left in kilodaltons 
(kDa). 
 
 
 
